tag:blogger.com,1999:blog-30069643288341397912024-03-05T00:56:47.603-08:00P.n.ramesh - Researchers Gate Way"Science knows no country, because knowledge belongs to humanity, and is the torch which illuminates the world"
------ Louis Pasteur
"Knowledge is not what you can remember, but what you cannot forget."
Learn something new.Try something different.Convince yourself that you have no limits.
------Brian Tracy
Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.comBlogger17125tag:blogger.com,1999:blog-3006964328834139791.post-54795120066200598362019-11-21T01:18:00.001-08:002019-11-21T01:18:42.165-08:00INTERNATIONAL CONFERENCE ON BACTERIOPHAGE RESEARCH AND ANTIMICROBIAL RESISTANCE - ICBRAMR<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="background-color: white; color: #222222; font-family: Arial, Helvetica, sans-serif; font-size: small;">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div dir="ltr">
<div>
<b style="font-family: Rockwell, serif; font-size: 11pt;"><span lang="EN-US">Dears!</span></b></div>
<div>
<b style="font-family: Rockwell, serif; font-size: 11pt;"><span lang="EN-US"><br /></span></b></div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="gmail_quote" style="background-color: white; color: #222222; font-family: Arial, Helvetica, sans-serif; font-size: small;">
<div dir="ltr">
<div dir="ltr">
<div class="gmail_quote">
<div dir="ltr">
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: 16.8667px; margin: 0cm 0cm 10pt; text-align: justify;">
<span lang="EN-US">Greeting from Vellore Institute of Technology!!!</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt; text-align: justify;">
<span lang="EN-US">I am glad to inform that our school of Bio Sciences and Technology-SBST & Society for Bacteriophage Research and Therapy-SBRT is organizing "<b><span style="color: #002060;"><span class="il">International</span> Conference on Bacteriophage Research and Antimicrobial Resistance” in VIT, Vellore.</span></b></span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt; text-align: justify;">
<span lang="EN-US">It’s my pleasure to welcome you for the forthcoming <span class="il">International</span> Conference to be held on 12<sup>th </sup>– 13<sup>th </sup>December 2019.</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt; text-align: justify;">
<span lang="EN-US">In this regard, I herewith enclose the brochure for your reference and we are pleased to inform that this information is also available on our website: <a data-saferedirecturl="https://www.google.com/url?q=http://www.vit.ac.in/&source=gmail&ust=1574409143184000&usg=AFQjCNH-pSW2SmFO_ZFrvADjOv6jUou8gw" href="http://www.vit.ac.in/" style="color: blue;" target="_blank">www.vit.ac.in</a><span style="color: blue; text-decoration-line: underline;">/<wbr></wbr>icbramr/</span>. I would be grateful if you could share this great scientific event with your colleagues and students.</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt; text-align: justify;">
<span lang="EN-US">Your contribution to this scientific event would be of immense value for the development of phage as an alternative treatment option and encountering the rising antibiotic resistance, in general, and Phage biology.</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt; text-align: justify;">
<span lang="EN-US">I am looking forward to your gracious presence to contribute your views and ideas on rising antibiotic resistance and phage therapy during the conference and make this event a grand success also kindly encourage your research students to submit their abstract.</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt;">
<span lang="EN-US" style="background-color: yellow;"><span style="color: red;">Abstract submission Date has extended</span></span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt;">
<span style="font-size: 11pt;">Thank you</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt;">
<span lang="EN-US">Kindly find the attached circular. </span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt;">
<span style="font-size: 11pt;">Looking forward to your presence!!!</span><span style="font-family: Arial, Helvetica, sans-serif; font-size: x-small;"> </span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: x-small;">Thank you</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: x-small;">Convener ICBRAMR-19</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: x-small;">Dr.Ramesh (Phage Man)</span></div>
<div class="MsoNormal" style="font-family: Rockwell, serif; font-size: 11pt; line-height: normal; margin: 0cm 0cm 10pt;">
<span style="font-family: Arial, Helvetica, sans-serif; font-size: x-small;">Plz visit us: </span><a href="https://vit.ac.in/ICBRAMR/" style="font-family: Arial, Helvetica, sans-serif; font-size: small;">https://vit.ac.in/ICBRAMR/</a></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEic7Q1QhsUbOZLlFmkSJNiRojxe3kK1B7GVP5xFoehpN9p3muTxL148Aq80uIYeZD_9gSul_ODBkKiBtfAAhYJFhkb6oedsq4iOn_dhkFo8baYN67V-EQeWk1EmLJvUNr_vPEpQuwQ7vj4/s1600/ICBRAMR-19.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="381" data-original-width="1287" height="94" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEic7Q1QhsUbOZLlFmkSJNiRojxe3kK1B7GVP5xFoehpN9p3muTxL148Aq80uIYeZD_9gSul_ODBkKiBtfAAhYJFhkb6oedsq4iOn_dhkFo8baYN67V-EQeWk1EmLJvUNr_vPEpQuwQ7vj4/s320/ICBRAMR-19.jpg" width="320" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhUUm79OmoUFtanZo3iNs7n4Fr1EqfXUT30b8g9sZKToKfg1FIYUS3TJ96dDjsEx_HI1BiH3q7usv6vEvOw1daW0adeqIFIIG2W5LWjip3fkl3-RkiuU3IjbqtpLWUU1J7O9MPT2ICIuVw/s1600/ICBR-Sponsor.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="720" data-original-width="960" height="240" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhUUm79OmoUFtanZo3iNs7n4Fr1EqfXUT30b8g9sZKToKfg1FIYUS3TJ96dDjsEx_HI1BiH3q7usv6vEvOw1daW0adeqIFIIG2W5LWjip3fkl3-RkiuU3IjbqtpLWUU1J7O9MPT2ICIuVw/s320/ICBR-Sponsor.jpg" width="320" /></a></div>
</div>
</div>
</div>
</div>
</div>
</div>
<div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com0tag:blogger.com,1999:blog-3006964328834139791.post-35256832142875160422017-11-12T23:26:00.001-08:002017-11-12T23:26:00.084-08:00India's First Nationwide Antimicrobial Resistance Awareness Campaign-2107- AMARC-17 by IIMAR<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjxKUlfqe14Nuv5RN552zJb7o2F_N2ewx0QPDw0shGtU9NtjpmoXsRdYiYVfM4ws_JAdtJq-eo6KjFWT3dQNmVN71US_kd1QuugA6pouEwd2WrxC3xzJVm6kYFMV7r9VyxfAotSAAjD078/s1600/AMRAC+poster.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1336" data-original-width="1600" height="267" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjxKUlfqe14Nuv5RN552zJb7o2F_N2ewx0QPDw0shGtU9NtjpmoXsRdYiYVfM4ws_JAdtJq-eo6KjFWT3dQNmVN71US_kd1QuugA6pouEwd2WrxC3xzJVm6kYFMV7r9VyxfAotSAAjD078/s320/AMRAC+poster.jpg" width="320" /></a></div>
<br /></div>
<div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com0tag:blogger.com,1999:blog-3006964328834139791.post-13291226203249407202017-10-24T02:45:00.003-07:002017-10-24T02:47:13.451-07:00<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto;">
<span style="font-family: "times new roman" , serif; font-size: 16px;"><b><span style="color: blue;">India's First National Level Antibiotic Resistance Awareness Program During 13th -19th Nov, 2017</span></b> <b><span style="color: blue;">by </span></b></span><span style="font-family: "times new roman", serif; font-size: 16px;"><b><span style="color: blue;">Indian Initiative for Management of Antibiotic Resistance-IIMAR</span></b></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto;">
<span style="font-family: "times new roman" , serif; font-size: 16px;"><br /></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto;">
<span style="font-family: "times new roman" , "serif"; font-size: 12.0pt;">We would like to bring this for your
kind knowledge that, Indian Initiative for Management of Antibiotic
Resistance-IIMAR (a non-profit and nongovernmental organization) is conducting India's first national level Antibiotic Resistance awareness program during 13th to 19th
November, 2017, jointly with National Center for Disease Control-NCDC, Govt of
India, New Delhi and Doctors For You-DFY etc., Mumbai by distributing pamphlets,
poster making, slogans, lectures, internet based social media. </span><span style="font-family: "times new roman" , serif; font-size: 12pt;">We also wish to disseminate the antibiotic
resistance awareness message through radio stations.</span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto;">
<span style="font-family: "times new roman" , serif; font-size: 12pt;"><br /></span></div>
<div class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0in; mso-margin-top-alt: auto;">
<span style="font-family: "times new roman" , serif; font-size: 12pt;">Those who wish to join pl mail us iimaraction@gmail.com/drpnramesh@gmail.com</span></div>
</div>
<div class="blogger-post-footer">Enable post feed additions</div>pnrameshhttp://www.blogger.com/profile/11828110185789159071noreply@blogger.com0tag:blogger.com,1999:blog-3006964328834139791.post-36430764712723822142016-07-19T05:00:00.002-07:002016-07-19T05:02:23.907-07:00<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="body" id="article-body" style="font-family: arial, Tahoma, Verdana, Helvetica, sans-serif; font-size: 12px; line-height: 1.5; margin-bottom: 15px;">
<div id="ES_Article_type" style="color: grey; font-size: 0.875em; font-weight: bold; line-height: normal; margin-top: 10px;">
Rapid communication</div>
<div id="ES_Article_title" style="font-size: 0.875em; font-weight: bold; line-height: 1.125em; text-transform: uppercase;">
</div>
<div id="ctl00_Place_ES_content_pnlContent" style="font-family: "Times New Roman"; font-size: medium; line-height: normal;">
<div id="article" style="font-size: 0.75em !important;">
<div class="front" id="article-front">
<div class="metadata centered" style="font-family: arial, Tahoma, Verdana, Helvetica, sans-serif;">
<div id="ES_Article_title" style="font-size: 1.2em; font-weight: bold; line-height: 1.125em; text-transform: uppercase;">
IDENTIFICATION OF A NOVEL PLASMID-MEDIATED COLISTIN-RESISTANCE GENE, <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MCR-2</i>, IN<i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">ESCHERICHIA COLI</i>, BELGIUM, JUNE 2016</div>
<div id="ES_Article_title" style="font-size: 1.2em; font-weight: bold; line-height: 1.125em; text-transform: uppercase;">
<br /></div>
</div>
</div>
</div>
</div>
<div class="first" id="ID0EWBAC">
Following the report of of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> detection in China in November 2015 [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r1" style="border-width: 0px !important; color: #003a80; text-decoration: none;">1</a>], we screened 105 colistin-resistant <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</i> (colistin minimum inhibitory concentration (MIC) 4–8 mg/L [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r2" style="border-width: 0px !important; color: #003a80; text-decoration: none;">2</a>]) isolated during 2011–12 from passive surveillance of diarrhoea in 52 calves and 53 piglets in Belgium [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r3" style="border-width: 0px !important; color: #003a80; text-decoration: none;">3</a>]. <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> was detected in 12.4% (n = 13) of the <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> isolates, of which six and seven were from calves and piglets, respectively [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r3" style="border-width: 0px !important; color: #003a80; text-decoration: none;">3</a>,<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r4" style="border-width: 0px !important; color: #003a80; text-decoration: none;">4</a>]. In the present study, we analysed porcine and bovine colistin-resistant <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</i> isolates that did not show presence of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> and identified a novel plasmid-mediated colistin resistance-conferring gene, <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i>.</div>
<div class="section">
<a href="https://draft.blogger.com/null" id="ID0E1CAC" style="border-width: 0px !important; color: #003a80;"></a><br />
<div class="section">
<a href="https://draft.blogger.com/null" id="ID0E3CAC" style="border-width: 0px !important; color: #003a80;"></a><br />
<h3 class="section-title" style="color: #365f91; font-size: 1.2em; font-style: italic; margin-bottom: 0px;">
Identification of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> in colistin-resistant <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> isolates not harbouring <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i></h3>
<div id="ID0EEDAC">
Of 92 porcine and bovine colistin-resistant <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</i> isolates not harbouring <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i>, 10 were randomly selected for further analysis. Plasmid DNA was isolated (PureLink HiPure Plasmid Miniprep Kit, Invitrogen, Carlsbad, CA, United States), sequenced by Illumina (2 x 250 bp) (Nextera XT sample preparation kit, MiSeq), de novo assembled and annotated using SPAdes (v3.8.1) and RAST [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r5" style="border-width: 0px !important; color: #003a80; text-decoration: none;">5</a>,<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r6" style="border-width: 0px !important; color: #003a80; text-decoration: none;">6</a>]. Plasmids from three of the 10 <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> isolates showed the presence of a gene for a putative membrane protein, which was identified as a phosphoethanolamine transferase (sulfatase) using pfam and Interproscan protein databases [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r7" style="border-width: 0px !important; color: #003a80; text-decoration: none;">7</a>,<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r8" style="border-width: 0px !important; color: #003a80; text-decoration: none;">8</a>] The <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> gene, as we termed it, is 1,617 bp long, nine bases shorter than <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> (1,626 bp), and shows 76.75% nt identity to <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> (supplementary material [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r9" style="border-width: 0px !important; color: #003a80; text-decoration: none;">9</a>]).</div>
<div id="ID0EGEAC">
The entire <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> gene was amplified (PCR primers: MCR2-F 5′ TGGTACAGCCCCTTTATT 3′; MCR2-R 5′ GCTTGAGATTGGGTTATGA 3′), cloned (vector pCR 2.1, TOPO TA Cloning kit, Invitrogen) and electroporated into DH-5 α<i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i>. Transformants exhibited colistin MICs of 4–8 mg/L (E-test, bioMerieux, Marcy l’Etoile, France), which were reconfirmed by macrobroth dilution (European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r2" style="border-width: 0px !important; color: #003a80; text-decoration: none;">2</a>]).</div>
</div>
<div class="section">
<a href="https://draft.blogger.com/null" id="ID0EQEAC" style="border-width: 0px !important; color: #003a80;"></a><br />
<h3 class="section-title" style="color: #365f91; font-size: 1.2em; font-style: italic; margin-bottom: 0px;">
<i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> is harboured on IS1595 with likely origins in <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella</i> spp.</h3>
<div id="ID0EXEAC">
<i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i>-harbouring plasmids from all three <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> isolates were analysed. The mobile element harbouring <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> was identified as an IS element of the IS1595 superfamily, which are distinguished by the presence of an ISXO2-like transposase domain [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r10" style="border-width: 0px !important; color: #003a80; text-decoration: none;">10</a>].</div>
<div id="ID0EDFAC">
We also identified a 297 bp open reading frame downstream of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> on this element, which encodes a PAP2 membrane-associated lipid phosphatase with 41% identity to <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella osloensis</i> phosphatidic acid phosphatase (71% query coverage). Interestingly, a blastn search of the IS1595 backbone, after removal of the <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> and <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">pap2</i>phosphatase gene sequences, identified a single hit to <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella bovoculi</i> strain 58069 (GenBank accession number CP011374) genomic region (1,531,602 to 1,532,255 bp) with 75% identity and 100% query coverage.</div>
</div>
<div class="section">
<a href="https://draft.blogger.com/null" id="ID0EPFAC" style="border-width: 0px !important; color: #003a80;"></a><br />
<h3 class="section-title" style="color: #365f91; font-size: 1.2em; font-style: italic; margin-bottom: 0px;">
<i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> is harboured on an IncX4 incompatibility-type plasmid in <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> ST10</h3>
<div id="ID0EWFAC">
The three <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> plasmid-harbouring <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> isolates belonged to ST10 (n = 2, porcine) and ST167 (n = 1, bovine). All three plasmids belonged to IncX4 incompatibility type; all three <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> genes showed 100% homology.</div>
<div id="ID0E5FAC">
Plasmid pKP37-BE isolated from one of the porcine ST10 <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> isolates was found to have a size of 35,104 bp, 41.3% GC content and 56 protein-encoding gene sequences (RAST) (<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#f1" style="border-width: 0px !important; color: #003a80; text-decoration: none;">Figure 1</a>); European Nucleotide Archive accession numbers PRJEB14596 (study) and LT598652 (plasmid sequence).</div>
<div class="fig panel" style="background: 0px 0px rgb(230, 239, 246); border: 1px solid rgb(230, 239, 246); margin: 10px 0px; padding: 10px;">
<div class="figure" style="background-color: white; border-radius: 3px; border: 1px solid rgb(215, 215, 215); font-size: 0.8em !important; margin: 0px; padding: 0px 6px 6px;">
<div class="table" id="tablef1" style="clear: both; line-height: 1.5; margin-bottom: 15px;">
<a href="https://draft.blogger.com/null" id="f1" style="border-width: 0px !important; color: #003a80;"></a><br />
<h3 class="label" style="color: #365f91; font-size: 13px !important;">
<span style="background-color: transparent; font-size: 12px; line-height: 1.5;">Apart from IS1595, pKP37-BE did not carry any other resistance genes and the plasmid backbone was highly similar to</span><i style="background-color: transparent; font-size: 12px; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica</i><span style="background-color: transparent; font-size: 12px; line-height: 1.5;"> subsp. </span><i style="background-color: transparent; font-size: 12px; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">enterica</i><span style="background-color: transparent; font-size: 12px; line-height: 1.5;"> serovar Heidelberg plasmid pSH146_32 (GenBank accession number JX258655), with 98% identity and 90% query coverage. Several </span><i style="background-color: transparent; font-size: 12px; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella</i><span style="background-color: transparent; font-size: 12px; line-height: 1.5;">-associated virulence genes were found on pKP37-BE, including </span><i style="background-color: transparent; font-size: 12px; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">virB</i><span style="background-color: transparent; font-size: 12px; line-height: 1.5;">/</span><i style="background-color: transparent; font-size: 12px; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D4</i><span style="background-color: transparent; font-size: 12px; line-height: 1.5;"> that encodes a type 4 secretion system [</span><a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r11" style="background-color: transparent; border-width: 0px; color: #003a80; font-size: 12px; line-height: 1.5; text-decoration: none;">11</a><span style="background-color: transparent; font-size: 12px; line-height: 1.5;">].</span></h3>
</div>
</div>
</div>
<div id="ID0ENHAC">
Conjugation experiments using a rifampicin-resistant <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> recipient (A15) showed an approximately 1,200-fold higher transfer frequency of the <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i>-harbouring pKP37-BE (1.71 × 10<span style="color: #666666; position: relative; top: -0.5em; vertical-align: top;">−3</span>) compared with the <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> harbouring IncFII plasmid, pKP81-BE (1.39 × 10<span style="color: #666666; position: relative; top: -0.5em; vertical-align: top;">−6</span>) [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r4" style="border-width: 0px !important; color: #003a80; text-decoration: none;">4</a>]. Both <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> and <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> transconjugants exhibited colistin MICs of 4–8 mg/L (macrobroth dilution).</div>
</div>
<div class="section">
<a href="https://draft.blogger.com/null" id="ID0EBIAC" style="border-width: 0px !important; color: #003a80;"></a><br />
<h3 class="section-title" style="color: #365f91; font-size: 1.2em; font-style: italic; margin-bottom: 0px;">
Structure predictions and phylogenetic analyses of the MCR-2 protein</h3>
<div id="ID0EDIAC">
MCR-2 protein was predicted to have two domains, with domain 1 (1 to 229 residues) as a transporter and domain 2 (230 to 538 residues) as a transferase domain (<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#f2" style="border-width: 0px !important; color: #003a80; text-decoration: none;">Figure 2</a>).</div>
<div class="fig panel" style="background: 0px 0px rgb(230, 239, 246); border: 1px solid rgb(230, 239, 246); margin: 10px 0px; padding: 10px;">
<div class="figure" style="background-color: white; border-radius: 3px; border: 1px solid rgb(215, 215, 215); font-size: 0.8em !important; margin: 0px; padding: 0px 6px 6px;">
<div class="table" id="tablef2" style="clear: both; line-height: 1.5; margin-bottom: 15px;">
<a href="https://draft.blogger.com/null" id="f2" style="border-width: 0px !important; color: #003a80;"></a><br />
<h3 class="label" style="color: #365f91; font-size: 13px !important;">
<span style="background-color: transparent; font-size: 12px; line-height: 1.5;">The best template for domain 1 was 4HE8, a secondary membrane transport protein with a role in transferring solutes across membranes [</span><a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r12" style="background-color: transparent; border-width: 0px; color: #003a80; font-size: 12px; line-height: 1.5; text-decoration: none;">12</a><span style="background-color: transparent; font-size: 12px; line-height: 1.5;">]. The best-fit template for domain 2 was 4kav (p = 4.13 e-13), a lipooligosaccharide phosphoethanolamine transferase A from </span><i style="background-color: transparent; font-size: 12px; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Neisseria meningitides</i><span style="background-color: transparent; font-size: 12px; line-height: 1.5;">, also previously shown to be the best-fit template for MCR-1 [</span><a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r1" style="background-color: transparent; border-width: 0px; color: #003a80; font-size: 12px; line-height: 1.5; text-decoration: none;">1</a><span style="background-color: transparent; font-size: 12px; line-height: 1.5;">]. 4kav belongs to the YhjW/YjdB/YijP superfamily and its role in conferring polymyxin resistance has been experimentally validated [</span><a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r13" style="background-color: transparent; border-width: 0px; color: #003a80; font-size: 12px; line-height: 1.5; text-decoration: none;">13</a><span style="background-color: transparent; font-size: 12px; line-height: 1.5;">]. Overall, the un-normalised global distance test (uGDT) was 318 (GDT: 58) and all 538 residues were modelled (</span><a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#f2" style="background-color: transparent; border-width: 0px; color: #003a80; font-size: 12px; line-height: 1.5; text-decoration: none;">Figure 2</a><span style="background-color: transparent; font-size: 12px; line-height: 1.5;">).</span></h3>
</div>
</div>
</div>
<div id="ID0ENJAC">
MCR-1 and MCR-2 proteins showed 80.65% identity (supplementary material [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r9" style="border-width: 0px !important; color: #003a80; text-decoration: none;">9</a>]). In addition, MCR-2 showed 64% identity to the phosphoethanolamine transferase of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella osloensis</i> (WP_062333180) with 99% sequence coverage, and 65%, 65%, and 61% identity to that of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Enhydrobacter aerosaccus</i> (KND21726), <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Paenibacillus sophorae</i>(WP_063619495) and <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella catarrhalis</i> (WP_003672704), respectively, all with 97% query coverage.</div>
<div id="ID0E2JAC">
We also carried out blastp searches of the two domains of MCR-2 separately. The identity level of domain 1 between MCR-1 and MCR-2 was low (72%) compared with that for domain 2 (87.4%). Other blastp hits for the domain 2 transferase were <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Enhydrobacter aerosaccus</i> and <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella osloensis</i> (69% identity; 100% query coverage) followed by<i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Paenibacillus sophorae</i> (68% identity; 100% query coverage) and <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella catarrhalis</i> (68% identity; 99% query coverage). Phylogenetic analysis showed that MCR-2 might have originated from <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella catarrhalis</i> (56% bootstrap value) (<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#f3" style="border-width: 0px !important; color: #003a80; text-decoration: none;">Figure 3</a>).</div>
<div class="fig panel" style="background: 0px 0px rgb(230, 239, 246); border: 1px solid rgb(230, 239, 246); margin: 10px 0px; padding: 10px;">
<div class="figure" style="background-color: white; border-radius: 3px; border: 1px solid rgb(215, 215, 215); font-size: 0.8em !important; margin: 0px; padding: 0px 6px 6px;">
<div class="table" id="tablef3" style="clear: both; line-height: 1.5; margin-bottom: 15px;">
<a href="https://draft.blogger.com/null" id="f3" style="border-width: 0px !important; color: #003a80;"></a><br />
<h3 class="label" style="color: #365f91; font-size: 13px !important;">
<span style="background-color: transparent; font-size: 1.2em; font-style: italic; line-height: 1.5;">PCR-based screening identified a higher prevalence of </span><i style="background-color: transparent; font-size: 1.2em; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i><span style="background-color: transparent; font-size: 1.2em; font-style: italic; line-height: 1.5;"> than of </span><i style="background-color: transparent; font-size: 1.2em; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i><span style="background-color: transparent; font-size: 1.2em; font-style: italic; line-height: 1.5;"> in porcine </span><i style="background-color: transparent; font-size: 1.2em; line-height: 1.5;" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i><span style="background-color: transparent; font-size: 1.2em; font-style: italic; line-height: 1.5;">in Belgium</span></h3>
</div>
</div>
</div>
</div>
<div class="section">
<div id="ID0E6KAC">
We screened our entire collection of porcine and bovine colistin-resistant <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> isolates (n = 105) using an <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2-</i>specific PCR approach using primers MCR2-IF 5’ TGTTGCTTGTGCCGATTGGA 3’ and MCR2-IR 5’ AGATGGTATTGTTGGTTGCTG 3’, and the following cycling conditions: 33 cycles of 95 °C × 3 min, 65 °C × 30 s, 72 °C × 1 min, followed by 1 cycle of 72 °C × 10 min. We found <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> in 11/53 porcine and 1/52 bovine colistin-resistant <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i>isolates (an overall prevalence of 11.4%).</div>
</div>
</div>
<div class="section">
<a href="https://draft.blogger.com/null" id="ID0EJLAC" style="border-width: 0px !important; color: #003a80;"></a><br />
<h2 class="main-title" style="color: #365f91; font-size: 1.3em;">
Discussion</h2>
<div id="ID0EMLAC">
Identification of plasmid-mediated colistin resistance represents a paradigm shift in colistin-resistance mechanisms, which until recently were restricted to chromosomal mutations and vertical transmission. Since <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> conferring plasmid-mediated colistin resistance was first detected in China, <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> has been identified in 32 countries across five continents [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r14" style="border-width: 0px !important; color: #003a80; text-decoration: none;">14</a>-<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r22" style="border-width: 0px !important; color: #003a80; text-decoration: none;">22</a>] (<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#f4" style="border-width: 0px !important; color: #003a80; text-decoration: none;">Figure 4</a>)*.</div>
<div class="fig panel" style="background: 0px 0px rgb(230, 239, 246); border: 1px solid rgb(230, 239, 246); margin: 10px 0px; padding: 10px;">
<div class="figure" style="background-color: white; border-radius: 3px; border: 1px solid rgb(215, 215, 215); font-size: 0.8em !important; margin: 0px; padding: 0px 6px 6px;">
<div class="table" id="tablef4" style="clear: both; line-height: 1.5; margin-bottom: 15px;">
<a href="https://draft.blogger.com/null" id="f4" style="border-width: 0px !important; color: #003a80;"></a><br />
<h3 class="label" style="color: #365f91; font-size: 13px !important;">
Figure 4</h3>
<div id="captionf4">
<div style="color: #365f91; font-size: 13px; line-height: 19.5px;">
Countries (n = 32)* reporting presence of <i>mcr-1</i> in samples of animal, environmental or human origin (data collected till 27 June 2016)</div>
</div>
<a href="https://draft.blogger.com/null" style="border-width: 0px !important; color: #003a80;"><img alt="/images/dynamic/articles/22525/16-00435-f4" src="https://www.eurosurveillance.org/images/dynamic/articles/22525/16-00435-f4.png" style="border-width: 0px !important; max-width: 600px;" /></a><br />
<br />
<javascript></javascript><br />
<div id="ID0EIMAC" style="font-size: 11px; line-height: 16.5px;">
Adapted from [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r15" style="border-width: 0px !important; color: #003a80; text-decoration: none;">15</a>]; updated using data from [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r14" style="border-width: 0px !important; color: #003a80; text-decoration: none;">14</a>,<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r16" style="border-width: 0px !important; color: #003a80; text-decoration: none;">16</a>-<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r22" style="border-width: 0px !important; color: #003a80; text-decoration: none;">22</a>]*.</div>
</div>
</div>
</div>
<div id="ID0E4MAC">
Our analysis identified a novel plasmid-mediated phosphoethanolamine transferase-encoding gene, <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i>, which was detected at an even higher prevalence than that of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> among colistin-resistant porcine <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> in our study. We were, however, limited by small sample numbers. It should also be noted that the calves and piglets were from different regions of the country (calves from Wallonia and piglets from Flanders).</div>
<div id="ID0EFNAC">
Phylogenetic analysis of MCR-2 provided strong evidence that this protein was distinct from MCR-1, and that it might have originated from <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella catarrhalis.</i> The latter set of data are further strengthened by the fact that <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> is co-harboured with a lipid phosphatase gene that shows highest homology to a phosphatase from <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella</i> spp., and that the genetic element IS1595 harbouring these two genes might itself have originated from <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella</i> spp. While<i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella</i> spp. are not polymyxin producers, this bacterial genus is known to be intrinsically resistant to polymyxins [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r23" style="border-width: 0px !important; color: #003a80; text-decoration: none;">23</a>] and potential intergeneric transfer of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> from co-habiting <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Moraxella</i> spp. of animal, human or environmental origin is therefore highly likely. Phosphoethanolamine transferases are housekeeping enzymes that catalyse the addition of the phosphoethanolamine moiety to the outer 3-deoxy-D-manno-octulosonic acid (Kdo) residue of a Kdo(2)-lipid A [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r24" style="border-width: 0px !important; color: #003a80; text-decoration: none;">24</a>]. The fact that we did not identify any chromosomal mutations in the known colistin resistance-conferring genes in our <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i>isolates (by whole genome sequencing, data not shown) additionally supports the role of the acquired phosphoethanolamine transferase in conferring colistin resistance.</div>
<div id="ID0E6NAC">
Finally, the high transfer frequency of the <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i>-harbouring IncX4 plasmid might underlie the higher prevalence of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i>in our porcine isolates. In the three <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> harbouring isolates analysed, IS1595 showed presence of direct repeats and a complete <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">tnpA</i> gene, while inverted repeats were not found (data not shown). However, the carrier plasmid IncX4 is itself highly transmissible, showing 10<span style="color: #666666; position: relative; top: -0.5em; vertical-align: top;">2</span>–10<span style="color: #666666; position: relative; top: -0.5em; vertical-align: top;">5</span>-fold higher transfer frequencies than, for instance, epidemic IncFII plasmids, as shown previously [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r25" style="border-width: 0px !important; color: #003a80; text-decoration: none;">25</a>] as well as in our own transconjugation experiments. Importantly, a lack of fitness-burden of IncX4 carriage on bacterial hosts [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r25" style="border-width: 0px !important; color: #003a80; text-decoration: none;">25</a>] makes this plasmid replicon a highly effective vehicle for dissemination of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i>. IncX4 plasmids have also been previously shown to harbour <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-1</i> [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r26" style="border-width: 0px !important; color: #003a80; text-decoration: none;">26</a>] as well as extended spectrum beta-lactamase genes, <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">bla</i><sub>CTX-M</sub> [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r25" style="border-width: 0px !important; color: #003a80; text-decoration: none;">25</a>]. Interestingly, the pKP37-BE backbone, which likely originated from <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella</i> spp., harboured a battery of virulence genes including the <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">virB4/D4</i> genes encoding a type-IV secretion system that has been shown to mediate downregulation of host innate immune response genes and an increased bacterial uptake and survival within macrophages and epithelial cells [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r11" style="border-width: 0px !important; color: #003a80; text-decoration: none;">11</a>]. Outer membrane modifications leading to colistin resistance have been shown to attenuate virulence [<a href="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525#r27" style="border-width: 0px !important; color: #003a80; text-decoration: none;">27</a>]: whether these co-harboured virulence genes are able to compensate the pathogenic abilities of colistin-resistant <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</i> remains to be explored.</div>
<div id="ID0ESPAC">
Taken together, these data call for immediate inclusion of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> screening in ongoing molecular epidemiological surveillance to gauge the worldwide dissemination of <i xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">mcr-2</i> in both human and animal colistin-resistant Gram-negative bacteria of medical importance.</div>
<div>
Source: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22525</div>
</div>
</div>
</div>
<div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com0tag:blogger.com,1999:blog-3006964328834139791.post-37717607586855514352013-10-10T23:43:00.001-07:002015-01-09T05:11:06.402-08:00<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: justify;">
</div>
<div class="" style="clear: both; text-align: center;">
</div>
<div class="" style="clear: both; text-align: center;">
</div>
<div class="body" itemprop="articleBody" style="text-align: justify;">
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="clear: right; float: left; margin-bottom: 1em; text-align: center;"><tbody>
<tr><td style="text-align: center;"></td></tr>
<tr><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td></tr>
</tbody></table>
<div class="articleHeader">
<span style="background-color: white; font-family: Georgia, 'Times New Roman', Times, serif; font-size: 30px; text-align: left;"><span style="color: red;">Massive breakthrough: Scientists create first new antibiotic in nearly 30 years</span></span><br />
<span style="background-color: white; color: #333333; font-family: Georgia, 'Times New Roman', Times, serif; font-size: 30px; text-align: left;"><br /></span>
<span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">LONDON: In a massive breakthrough, scientists have created the first new antibiotic in more than three decades, Teixobactin, that can treat many common bacterial infections such as tuberculosis, septicemia and C Diff or clostridium difficile colitis. </span><br />
<br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">The discovery comes at a time when World Health Organization has sent out warnings that humanity is staring at a post-antibiotic era when common infections will no longer have a cure. The first antibiotic, Penicillin, was discovered by Alexander Fleming in 1928, and more than 100 compounds have been found since then, but no new class has been found since 1987. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">Antibiotics have been magic bullets for human health for decades but irrational use has made most bugs resistant to these. Northeastern University's professor Kim Lewis announced Thursday the discovery of the antibiotic that eliminates pathogens without encountering any detectable resistance. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">Lewis and Northeastern biology professor Slava Epstein coauthored the finding with colleagues from the University of Bonn in Germany, Novo Biotic Pharmaceuticals in Cambridge, Massachusetts, and Selcia Ltd in the United Kingdom. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">Most antibiotics target bacterial proteins, but bugs can become resistant by evolving new kinds of proteins. What's unique about Teixobactin is that it launches a double attack on the building blocks of bacterial cell walls. Experts say this will pave the way for a new generation of antibiotics because of the way it was discovered. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">Teixobactin could be available in the next five years. Its testing on mice has shown it clears infections without side-effects. The NU team led by Prof Lewis is now concentrating on upscaling production of Teixobactin to test it on humans. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">Northeastern researchers' pioneering work to develop a novel method for growing uncultured bacteria led to the discovery of the antibiotic, and Lewis's lab played a key role in analyzing and testing the compound for resistance from pathogens. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">Lewis said this marks the first discovery of an antibiotic to which resistance by mutations of pathogens have not been identified. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">"So far, the strategy has been based on developing new antibiotics faster than the pathogens acquire resistance. Teixobactin presents a new opportunity to develop compounds that are essentially free of resistance," Lewis said. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">The screening of soil micro-organisms has produced most antibiotics, but only one per cent of these will grow in the lab, Lewis explained. He and Epstein spent years seeking to address this problem by tapping into a new source of antibiotics beyond those created by synthetic means: uncultured bacteria, which make up 99% of all species in external environments. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">They developed a novel method for growing uncultured bacteria in their natural environment. Their approach involves the iChip, a miniature device Epstein's team created that can isolate and help grow single cells in their natural environment and provide researchers with much improved access to uncultured bacteria. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">"Novo Biotic has assembled about 50,000 strains of uncultured bacteria and discovered 25 new antibiotics, of which Teixobactin is the latest and most interesting," Lewis said. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">"Our impression is that nature produced a compound that evolved to be free of resistance," Lewis said. "This challenges the dogma that we've operated under that bacteria will always develop resistance. Well, maybe not in this case." </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">Britain's chief medical officer, Dame Sally Davies, recently said antibiotic resistant was "as big a risk as terrorism", and warned that Britain faced returning to 19th century scourges when the smallest infection or operations could kill. </span><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><br style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; margin: 0px; padding: 0px; text-align: left;" /><span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">WHO said a comprehensive study of antibiotic development, covering innovative, small firms, as well as pharmaceutical giants found that only 15 out of 167 antibiotics under development had a new mechanism of action with the potential to meet the challenge of multidrug resistance. </span><br />
<span style="background-color: white; color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px; text-align: left;">Reff:</span><span style="color: cyan; font-family: georgia; font-size: x-small;"><span style="line-height: 20px;">http://timesofindia.indiatimes.com/home/science/Massive-breakthrough-Scientists-create-first-new-antibiotic-in-nearly-30-years/articleshow/45807598.cms</span></span><br />
<b><br /></b>
<b><img alt="" height="240" src="data:image/jpeg;base64,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" width="320" /> </b><br />
<div style="text-align: center;">
<span style="color: blue;"><b>We are cordially inviting you to participate in our knowledge carnival <span style="font-size: large;"><span style="color: red;">graVITas'14</span></span> at </b></span></div>
<div style="text-align: center;">
<span style="color: blue;"><b>VIT University, Vellore, TN, India. <span style="color: #cc0000;">Click us</span> <a href="http://vitgravitas.com/">http://vitgravitas.com/ </a></b></span><br />
<span style="color: blue;"><b> <a href="http://www.vit.ac.in/">www.vit.ac.in</a></b></span></div>
<b></b>
<b>----------------------------------------------------------------------------------------------------------------------------- </b><br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-size: large;"><span style="color: orange;"><b>Superbugs threaten a return to the ‘dark ages’</b></span></span><br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="clear: right; float: left; margin-bottom: 1em; text-align: center;"><tbody>
<tr><td style="text-align: center;"><br /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td></tr>
</tbody></table>
Britain will lead the fightback against antibiotic-resistant
superbugs threatening to send medicine "back into the dark ages", David
Cameron has said.</td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td><td class="tr-caption" style="text-align: center;"><b><br /></b></td></tr>
</tbody></table>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"></a></div>
The Prime Minister said resistance to antibiotics was a "very real
and worrying threat" and could lead to a future in which currently
treatable injuries and ailments could prove fatal.<br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="clear: right; float: right; margin-bottom: 1em; text-align: center;"><tbody>
<tr><td style="text-align: center;"><br /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"><br /></td></tr>
</tbody></table>
<a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791#allposts/src=dashboard" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><a href="https://draft.blogger.com/blogger.g?blogID=3006964328834139791" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a>As part of the effort to address the issue an international group of
experts will aim to stimulate the development of a "new generation of
antibiotics", The Times reported.<br />
"This is not some distant threat but something happening right now,"
Mr Cameron told the newspaper. "If we fail we are looking at an almost
unthinkable scenario where antibiotics no longer work and we are cast
back into the dark ages of medicine where treatable infections and
injuries will kill once again.<br />
"That simply cannot be allowed to happen and I want to see a stronger, more coherent global response." <br />
Former Goldman Sachs chief economist Jim O'Neill will lead the
international expert group and has been asked to consider how
governments would pay pharmaceutical companies to produce drugs even if
they were rarely used. <br />
The group will also consider how poorer countries can be encouraged to improve control of existing antibiotics. <br />
The Prime Minister told The Times: " I've been listening to the
scientific advice that I get, and the network of advisers we have are
all saying this is one of the most serious health problems the world
faces. <br />
"For many of us we only know a world where infections or sicknesses
can be quickly remedied by a visit to the doctor and a course of
antibiotics. <br />
"This great British discovery has kept our families safe for decades, while saving billions of lives around the world. <br />
<div class="articleInsert clearfix">
<div class="clearfix" id="google-ads-container2">
</div>
</div>
"But that protection is at risk as never before. Resistance to antibiotics is now a very real and worrying threat." <br />
He added: "When we've had these problems in the past, whether it
is how we tackle HIV and Aids, how it is possible to lead the world
and get rid of diseases like polio, Britain has taken a lead and I
think it is right we take a lead again." <br />
The Prime Minister raised the issue privately with US president
Barack Obama and German chancellor Angela Merkel during the G7 summit
last month. <br />
The initial £500,000 cost of the work will be met by the Wellcome
Trust, whose director Jeremy Farrar said: "Drug-resistant bacteria,
viruses and parasites are driving a global health crisis. <br />
"It threatens not only our ability to treat deadly infections, but
almost every aspect of modern medicine: from cancer treatment to
Caesarean sections, therapies that save thousands of lives every day
rely on antibiotics that could soon be lost. <br />
"We are failing to contain the rise of resistance, and failing to
develop new drugs to replace those that no longer work. We are heading
for a post-antibiotic age. <br />
"This is not just a scientific and medical challenge, but an economic
and social one too. I am thus delighted that an economist of the
stature of Jim O'Neill has agreed to investigate these issues, with an
eye on the incentives, regulatory systems and behavioural changes that
will be required to resolve them.<br />
"The Wellcome Trust is proud to fund and host Jim and his team as they conduct this vital work.<br />
"Drug-resistant infection is one of the most urgent challenges of our
time. It demands the attention of world leaders and international
action, which is why it is encouraging that David Cameron is taking the
issue so seriously and giving it the profile it deserves."<br />
Professor Dame Sally Davies, the chief medical officer for England,
said: "We must act now on a global scale to slow down antimicrobial
resistance. <br />
"In Europe, at least 25,000 people a year already die from
infections which are resistant to our drugs of last resort. New
antibiotics made by the biotech and pharmaceutical industry will be
central to resolving this crisis which will impact on all areas of
modern medicine. <br />
"I am delighted to see the Prime Minister taking a global lead by
commissioning this review to help new antibiotics to be developed and
brought to patients effectively."<br />
<br />
<h1 class="story-header">
Antibiotic resistance: Cameron warns of medical 'dark ages'</h1>
<br />
<div class="introduction">
The world could soon be "cast back into the dark
ages of medicine" unless action is taken to tackle the growing threat
of resistance to antibiotics, Prime Minister David Cameron has said. </div>
He has announced a review into why so few anti-microbial drugs have been introduced in recent years.<br />
Economist Jim O'Neill will lead a panel including experts from science, finance, industry, and global health.<br />
It will set out plans for encouraging the development of new antibiotics.<br />
<span class="cross-head">'Taking the lead'</span>
The prime minister said: "If we fail to act, we are looking at
an almost unthinkable scenario where antibiotics no longer work and we
are cast back into the dark ages of medicine where treatable infections
and injuries will kill once again."<br />
Mr Cameron said he discussed the issue at a G7 leaders
meeting in Brussels earlier this month and got specific support from US
President Barack Obama and German Chancellor Angela Merkel.<br />
It is hoped that the review panel's proposals will be discussed at next year's G7 summit, which will be hosted by Germany.<br />
"Penicillin was a great British invention by Alexander
Fleming back in 1928," Mr Cameron told the BBC. "It's good that Britain
is taking the lead on this issue to solve what could otherwise be a
really serious global health problem."<br />
He said the panel would analyse three key issues: the
increase in drug-resistant strains of bacteria, the "market failure"
which has seen <a href="http://reports.weforum.org/global-risks-2013/view/risk-case-1/the-dangers-of-hubris-on-human-health/#/view/fig-18">no new classes of antibiotics for more than 25 years,</a> and the over-use of antibiotics globally.<br />
<span class="cross-head">'Time bomb'</span>
It is estimated that drug-resistant strains of bacteria are
responsible for 5,000 deaths a year in the UK and 25,000 deaths a year
in Europe.<br />
<div class="caption full-width">
<img alt="bacteria" src="http://news.bbcimg.co.uk/media/images/75984000/jpg/_75984605_b2340108-resistant_staphylococcus_bacteria,_tem-spl.jpg" height="179" width="320" />
<span style="width: 624px;">A resistant strain of bacteria</span>
</div>
Chief Medical Officer for England Prof Dame Sally Davies has
been a key figure helping to get the issue on the government and global
agenda. <br />
Last year she described the threat of antimicrobial
resistance as a "ticking time bomb" and said the dangers it posed should
be ranked along with terrorism.<br />
She spoke at a meeting of scientists at the Royal Society
last month which warned that a response was needed akin to efforts to
combat climate change.<br />
Dame Sally said: "I am delighted to see the prime minister taking a global lead by commissioning this review. <br />
"New antibiotics made by the biotech and pharmaceutical
industry will be central to resolving this crisis which will impact on
all areas of modern medicine." <br />
<div class="caption body-narrow-width">
<img alt="Antibiotics dates of discovery timeline" src="http://news.bbcimg.co.uk/media/images/66324000/gif/_66324987_antibiotics_timeline_nodates__304.gif" height="899" width="304" />
</div>
Medical research charity the Wellcome Trust is providing
£500,000 of funding for Mr O'Neill and his team, which will be based at
their headquarters in central London.<br />
Antimicrobial resistance has been a key issue for Jeremy Farrar, since he became director of the Wellcome Trust last year. <br />
"Drug-resistant bacteria, viruses and parasites are driving a global health crisis," he said. <br />
"It threatens not only our ability to treat deadly
infections, but almost every aspect of modern medicine: from cancer
treatment to Caesarean sections, therapies that save thousands of lives
every day rely on antibiotics that could soon be lost."<br />
<span class="cross-head">'Market failure'</span>
Antibiotics have been an incredible success story, but bacteria eventually develop resistance through mutation. <br />
One example is MRSA, which has been a major threat for years
in hospitals. It is resistant to all but the most powerful of
antibiotics, and the main weapon against it is improved hygiene, which
cuts the opportunity for infection to spread. <br />
Without antibiotics a whole raft of surgical procedures would
be imperilled, from hip replacements to cancer chemotherapy and organ
transplants.<br />
Before antibiotics, many women died after childbirth after developing a simple bacterial infection. <br />
Mr O'Neill is a high-profile economist who is best-known for
coining the terms Bric and Mint - acronyms to describe countries which
are emerging and potential powerhouses of the world economy. <br />
He is not, though an expert on antibiotics or microbes. But
Mr Cameron told the BBC it was important to have an economist heading
the review: <br />
"There is a market failure; the pharmaceutical industry
hasn't been developing new classes of antibiotics, so we need to create
incentives."<br />
Jeremy Farrar said: "This is not just a scientific and
medical challenge, but an economic and social one too which would
require analysis of regulatory systems and behavioural changes to solve
them."<br />
Mr O'Neill will begin work in September and is expected to deliver his recommendations next spring.<br />
Last month antibiotic resistance was selected as the focus
for the £10m Longitude Prize, set up to tackle a major challenge of our
time. <br />
<br />
<h2 class="f-ha">
<span style="font-size: x-small;"> http://www.guardian-series.co.uk/uk_national_news/11313176.UK_to_lead_superbug_fight___Cameron/</span></h2>
<h2 class="f-ha">
</h2>
<h2 class="f-ha">
</h2>
<h2 class="f-ha">
<span id="goog_1772391313"></span><span id="goog_1772391314"></span> </h2>
<span style="color: blue; font-size: x-small;">Reff: The Times of London-Twitter, http://www.bbc.com/news/health-28098838</span><br />
------------------------------------------------------------------------------------------------------------------------------<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><br /></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"><br /></td></tr>
</tbody></table>
<span style="color: blue;"><span style="font-size: large;">How a Microbe Resists Its Own Antibiotics</span></span></div>
<div class="articleHeader">
<br />
<div class="articleHeader">
<div class="summary" itemprop="description">
Researchers reveal the molecular mechanisms of <i>Streptomyces platensis</i>’s defense from its own antibiotics, which inhibit fatty acid synthesis in other microbes.</div>
<div class="subHeader">
<span class="authors">By <span itemprop="author">Jef Akst</span></span> | <span class="date">February 20, 2014</span>
</div>
</div>
<div class="articleSocialMedia">
<ul class="internalMedias">
<li class="comments"><a href="http://www.the-scientist.com/?articles.view/articleNo/39237/title/How-a-Microbe-Resists-Its-Own-Antibiotics/#articleComments"><span class="icon"></span></a><span class="imageBlock" style="display: inline-block; width: 310px;"><img alt="" src="http://www.the-scientist.com/images/News/February2014/Streptomyces.jpg" height="207" title="" width="310" /><span class="caption">Slide culture of a <i>Streptomyces </i>species </span><span class="reference">WIKIMEDIA, <a href="http://commons.wikimedia.org/wiki/File:Streptomyces_sp_01.png" target="_blank">CDC PUBLIC HEALTH IMAGE LIBRARY</a></span></span>In the mid-2000s, scientists identified two novel antimicrobial compounds in the bacterium <i>Streptomyces platensis</i>,
each of which target a different enzyme involved in fatty acid
synthesis in other microbes. Platensimycin and platencin are now being
explored as a new class of antibiotics. Research published today
(February 20) in <i>Chemistry & Biology</i> from investigators at
the University of Wisconsin-Madison and The Scripps Research Institute
in Jupiter, Florida, details the mechanism by which <i>S. platensis </i>protects
itself from its own antibiotics: the bacterium employs an enzyme during
fatty acid synthesis that is unaffected by the compounds.</li>
</ul>
</div>
<div class="body" itemprop="articleBody">
“It is a nice piece of work and is perhaps one of the first complete
demonstrations of antibiotic resistance mechanisms from genome
sequencing information,” microbiologist <a href="http://www.microbiology.ubc.ca/research/labs/davies" target="_blank">Julian Davies</a>, a professor emeritus at the University of British Columbia who was not involved in the work, told <i>The Scientist </i>in an e-mail.<br />
“The novelty is in the detail here,” agreed <a href="https://www.jic.ac.uk/profile/david-hopwood.asp" target="_blank">David Hopwood</a>,
former head of the genetics department and now emeritus fellow at the
John Innes Centre, who also did not participate in the research. “It
tells us a lot of interesting things about fatty acid biosynthesis in
bacteria . . . [and] about the way that the antibiotics interact with
[that] pathway.”<br />
Since researchers first identified platensimycin and platencin, they
have questioned how the compounds do not disrupt the synthesis of <i>S. platensis</i>’s
own fatty acids. “If the organism is making an antibiotic which is
potentially lethal, it has to protect itself,” Hopwood said. “So almost
always an antibiotic producer has self-protecting mechanisms.”<br />
To identify those mechanisms, Scripps microbiologist <a href="http://www.scripps.edu/florida/research/faculty/shen" target="_blank">Ben Shen</a> and his colleagues performed bioinformatics analyses of the open reading frames in the genomes of two strains of <i>S. platensis</i>
and identified four genes that, based on their homology to enzymes of
known function and their apparent lack of a role in antibiotic
biosynthesis, the researchers hypothesized may confer resistance to
platensimycin and platencin. Follow-up experiments revealed that the
enzyme PtmP3, which is resistant to the antibiotics, had replaced two
fatty acid biosynthesis enzymes, FabF and FabH, which are normally
inhibited by the compounds, and expression of PtmP3 in the normally
susceptible <i>S. albus</i> rendered the bacteria resistant to both antibiotics. Moreover, <i>S. platensis</i>’s
FabF had evolved structural changes so as to be resistant to
platensimycin, serving as “a second form of self-resistance,” the
authors wrote.<br />
Similar self-resistance mechanisms were previously identified in other bacteria—for example, in <i>Pantoea agglomerans</i>,
which produces the antimicrobial compound andrimid. “The way the
producing bacterium copes with this dilemma is to make its own enzyme
resistant to the inhibitor,” microbiologist and biochemist <a href="http://mcb.illinois.edu/faculty/profile/jecronan/" target="_blank">John Cronan</a>
at the University of Illinois at Urbana-Champaign, who was not involved
in the work, wrote in an e-mail. “[T]his is essentially the same
message that the Shen paper reports.”<br />
Whether the findings could inform platensimycin and platencin
development efforts remains to be seen, however. “[B]oth compounds have
poor pharmacokinetics,” Cronan noted. “They have too high a rate of
clearance in the body and gram negative bacteria are resistant due to
efflux pumps. . . . As far as the future of these compounds my guess is
that they will fail (or have already failed).”<br />
Nevertheless, Shen and his colleagues are hopeful that understanding how <i>S. platensis</i> protects itself will yield insight that could aid the development of platensimycin and platencin.<br />
“Development of resistance in pathogenic bacteria has widely been
attributed to horizontal gene transfer from nonpathogenic bacteria with
one potential source being antibiotic-producing bacteria that developed
highly effective mechanisms to avoid suicide,” the authors wrote in
their paper. “Understanding self-resistance mechanisms within
[platensimycin] and [platencin] producing organisms therefore is
imperative for predicting, determining, and thereby managing, potential
resistance that could develop with any future use of [these drugs] or
their derivatives in the clinic.”<br />
<b>R.M. Peterson et al., “Mechanisms of self-resistance in the
platensimycin and platencin producing Streptomyces platensis MA7327 and
MA7339 strains,” Chemistry & Biology, 2014. </b></div>
<h2 itemprop="name">
<span style="font-size: xx-small;"><span style="color: #a2c4c9;"> Reff.:The.Scientist.com</span></span></h2>
<h2 itemprop="name">
<span style="color: #a2c4c9;">
</span><span style="color: blue;">------------------------------------------------------------------------------------ </span></h2>
<h2 itemprop="name">
<span style="color: blue;">Early Evidence</span></h2>
<div class="summary" itemprop="description">
Fossilized structures suggest that mat-forming microbes have been around for almost 3.5 billion years.</div>
<div class="subHeader">
<span class="authors">By <span itemprop="author">Abby Olena</span></span> | <span class="date">March 1, 2014</span>
</div>
</div>
<div class="body" itemprop="articleBody">
<span class="imageBlock" style="display: inline-block; float: left; margin-bottom: 10px; margin-right: 10px; width: 310px;"><img alt="" src="http://www.the-scientist.com/images/March2014/SHORTLIT1.jpg" height="232" title="" width="310" /><span class="caption">OLD
MICROBES: These chips in the rocks of Western Australia’s Dresser
Formation are thought to have been made by ancient microbial mats.</span><span class="reference">COURTESY NORA NOFFKE</span></span><br />
<h3>
<span style="font-size: small;"><span style="color: orange;">EDITOR'S CHOICE IN EVOLUTION/GEOBIOLOGY</span></span></h3>
<b>The paper</b><br />
N. Noffke et al., “Microbially induced sedimentary structures recording
an ancient ecosystem in the ca. 3.48 billion-year-old Dresser
Formation, Pilbara, Western Australia,” <a href="http://online.liebertpub.com/doi/abs/10.1089/ast.2013.1030" target="_blank"><i>Astrobiology</i></a>, 13:1103-24, 2013.<br />
<br />
<b>The background</b><br />
Modern microorganisms leave traces on substrates called microbially
induced sedimentary structures (MISS)—textures that arise from a biofilm
or microbial mat interacting with the dynamics of the sediments upon
which it forms. Until recently, the oldest fossilized MISS, located in
South Africa, dated back to 3.2 billion years ago. However, evidence
from microfossils and stromatolites, another rock structure shaped by
bacteria, suggests that microbes existed at least 200 million years
earlier.<br />
<br />
<b>The evidence</b><br />
In the Dresser Formation in Western Australia—one of the only places in
the world with well-preserved 3.48-billion-year-old rocks—Nora Noffke
of Old Dominion University in Norfolk, Virginia, and colleagues recorded
microtextures characteristic of biofilms and microbial mats and
uncovered geochemical signals consistent with a biological origin. The
morphology and distribution of the fossils in this ancient coastal salt
flat strongly resembled modern MISS.<br />
<br />
<b>The significance</b><br />
The finding “supports interpretations that life had evolved before 3.4
billion years [ago], as indicated by the presence of both stromatolites
and microfossils,” Kath Grey, who is the former chief paleontologist of
the Geological Survey of Western Australia and was not involved in the
research, wrote in an e-mail to <i>The Scientist.</i> According to
Noffke, the fossilized MISS’s similarities to contemporary MISS suggest
that ancient biofilms behaved in the same way that modern microbes do.<br />
<br />
<b>The origins</b><br />
The Mars rover is currently hunting for MISS as a sign of life. Here on
Earth, the origin of life predates the fossils from the Dresser
Formation. Even 3.5 billion years ago, “life is already so complex,”
Noffke says. “Its evolution must have taken a lot of time.”<br />
<span style="color: #a2c4c9;"><span style="font-size: xx-small;">Reff: The.Scientist.com</span></span> </div>
<h2 itemprop="name" style="text-align: justify;">
<span style="color: blue;"><span style="background-color: white;">------------------------------------------------------------------------------------</span></span></h2>
<h2 itemprop="name" style="text-align: justify;">
<span style="color: blue;"><span style="background-color: white;">Outwitting the Perfect Pathogen</span></span></h2>
<div style="text-align: justify;">
<span class="imageBlock" style="display: inline-block; margin-bottom: 10px; width: 640px;"></span></div>
<div style="text-align: justify;">
<span class="imageBlock" style="display: inline-block; margin-bottom: 10px; width: 640px;"></span></div>
<div style="text-align: justify;">
<span class="imageBlock" style="display: inline-block; margin-bottom: 10px; width: 640px;"><img alt="" src="http://www.the-scientist.com/images/January2014/biobiz.jpg" height="180" title="" width="320" /><span class="caption"> </span></span></div>
<div style="text-align: justify;">
<span class="imageBlock" style="display: inline-block; margin-bottom: 10px; width: 640px;"><span class="caption">WORLDWIDE
PATHOGEN: About one-third of the human population is infected with
Mycobacterium tuberculosis (cultures shown above), some 13 million of
which are actually sick with TB.</span><span class="reference">CDC/GEORGE KUBICA</span></span></div>
<div style="text-align: justify;">
<span class="dropcap">I</span>n 2009, an international consortium of
researchers initiated an efficacy trial for a new tuberculosis (TB)
vaccine—the first in more than 80 years. With high hopes, a team led by
the South African Tuberculosis Vaccine Initiative inoculated 2,797
infants in the country, half with a vaccine called MVA85A and half with a
placebo. They followed the children for up to three years and finally
announced the result last February. It was not good news (<a href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2960177-4/abstract" target="_blank"><i>Lancet</i></a>, 381:1021-28, 2013).</div>
<div style="text-align: justify;">
“It did not work,” says Thomas Evans, president and CEO of Aeras, the
Rockville, Maryland-based nonprofit that sponsored the trial. The
vaccine did not protect children against the deadly disease.</div>
<div style="text-align: justify;">
“The whole field was disappointed,” says Robert Ryall, TB vaccine
project leader at Sanofi Pasteur, who was not involved in the trial.
“And unfortunately the field did not learn much.” The vaccine developers
still do not know why MVA85A didn’t work.</div>
<div style="text-align: justify;">
The only vaccine currently available in the fight against TB is Bacille
Calmette-Guérin (BCG), a live vaccine first used in 1921 and originally
derived from a cow tuberculosis strain. Though the exact mechanism of
the vaccine’s protection remains unclear, researchers do know that it
doesn’t work well: it reduces the risk of a form of TB that is
especially lethal to infants, but it does not reliably protect against
TB lung infections, which kill more than a million adults worldwide each
year.</div>
<div style="text-align: justify;">
With every cough or sneeze of an infected individual, TB bacilli fly
through the air, and to date have spread to one-third of the world’s
population. In most individuals, <i>Mycobacterium tuberculosis (Mtb)</i>
lie dormant, never causing sickness. In others, however, the bacteria
cause life-threatening lung infections. Some 13 million people around
the world are actively sick with TB, and someone dies of the disease
approximately every 20 seconds, according to the World Health
Organization (WHO).</div>
<div style="text-align: justify;">
“The need for a TB vaccine is enormous,” says David Sherman, a
tuberculosis expert at the nonprofit Seattle Biomedical Research
Institute. And an inadequate vaccine is not the field’s only problem:
the four main drugs currently used to treat tuberculosis are also
decades old, take six months to rid the body of the bacilli, and are
becoming obsolete due to the spread of multidrug-resistant and
extensively drug-resistant TB. Despite the gloomy outlook, many
researchers are still plugging away, through pharmaceutical-nonprofit
partnerships and redesigned basic research efforts, to achieve a happy
ending.</div>
<h3 style="text-align: justify;">
Ancient foe</h3>
<div style="text-align: justify;">
<span class="imageBlock" style="display: inline-block; float: right; margin-bottom: 10px; margin-left: 10px; width: 310px;"><img alt="" src="http://www.the-scientist.com/images/January2014/TB.jpg" height="207" title="" width="310" /><span class="caption">BATTLING
TB: Paula Fujiwara (left) of the International Union Against
Tuberculosis and Lung Disease speaks with a woman who is serving as the
treatment supervisor of her 25-month-old child with TB.</span><span class="reference">WHO/TBP/GARY HAMPTON</span></span>Tuberculosis
has plagued humans for thousands of years. Even ancient Egyptians were
ravaged by TB, as evidence from mummies has shown. And over those
millennia, <i>Mtb</i> has learned to quietly, carefully live within the human body.</div>
<div style="text-align: justify;">
“It’s not just a pathogen; in some ways it’s commensal,” says Evans.
“It’s been dealing with the human immune system for a long period of
time and knows how to go latent and keep itself transmitted.” Of the
roughly 2 billion people infected with Mtb, about 90 percent will never
get sick, though they are a vast reservoir of the bacteria, fueling the
epidemic. And when illness occurs, unlike many infections that involve
an acute sickness as the host’s immune system battles the pathogen,
tuberculosis infection resembles a chronic disease. “Everything about
the infection is slowed down, frankly, in ways we don’t understand,”
says Sherman.</div>
<div style="text-align: justify;">
<i>E. coli</i>, for example, replicates so quickly—about once every 20 minutes—that one cell can grow into a colony of a million overnight. <i>Mtb</i>,
on the other hand, only doubles once every 20 hours, and would take
three weeks to grow a colony of similar size. Additionally, the human
immune system produces antibodies against most pathogens in roughly 5 to
7 days. Antibody production against <i>Mtb</i> takes three weeks,
likely because the bacteria are slow to travel to the lymph nodes where
an adaptive immune response commences. “TB is exquisitely adapted to
long-term survival in a human host,” says Sherman.</div>
<div style="text-align: justify;">
The current TB drug regimen relies on a six-month treatment of four
antibiotics, all discovered in the 1950s and ’60s and which primarily
inhibit cell-wall and RNA synthesis. (See illustration.) Worldwide,
about 3.6 percent of new TB cases and 20 percent of recurring infections
are multidrug resistant, according to the WHO.</div>
<div style="text-align: justify;">
<blockquote>
<i>Mtb</i> is not just a pathogen; in some ways it’s commensal.<br />
<span style="color: black; float: right; font-family: Arial, sans-serif; font-size: 12px; line-height: 18px; margin: 0 0 0 0; text-align: right;">—Thomas Evans, Aeras</span></blockquote>
</div>
<div style="text-align: justify;">
Unfortunately, there isn’t a deep pipeline of drug candidates to fall
back on. It wasn’t until December 2012, some 50 years after the last
first-in-class approvals, that the US Food and Drug Administration
approved a TB drug with a new mechanism of action. Janssen Therapeutics’
bedaquiline (Sirturo) inhibits an ATP synthase enzyme in the
bacterium’s cell membrane to prevent the pathogen from generating energy
and replicating. (See illustration.) No other anti-TB drugs are close
to approval.</div>
<div style="text-align: justify;">
TB drug development has been slow for several reasons. For one, the
drugs are difficult and expensive to make, and they are primarily needed
in developing countries that can’t afford to pay top dollar for a
six-month drug regimen. “Working in TB will not drive profit for
pharmaceutical companies,” says Manos Perros, head of AstraZeneca’s
Boston-based Infection Innovative Medicines Unit. As a result, most
recent TB drug development has involved collaborations between big
pharma and government institutions or nonprofit advocacy organizations,
as well as academia. These are “partnerships that bring resources and
funding that make this kind of work, frankly, possible,” says Perros.
“This is a space where competitions between pharma and academia are
unfruitful.”</div>
<div style="text-align: justify;">
Other pharma companies share that sentiment. In February 2013,
Glaxo-SmithKline (GSK) opened up the closely guarded doors of their
laboratories to share information with the TB research community about
177 compounds from the company’s pharmaceutical library that appear to
inhibit <i>Mtb</i> (<a href="http://www.ncbi.nlm.nih.gov/pubmed/23307663" target="_blank"><i>ChemMedChem</i></a>,
8:313-21, 2013). The set of compounds has already been sent to nine
groups in the U.K., U.S., Canada, The Netherlands, France, Australia,
Argentina, and India, according to GSK spokesperson Melinda Stubbee.</div>
<div style="text-align: justify;">
But even with this collaborative attitude, the research community has
struggled to develop successful new TB drugs, in part because the
bacterium hides latent inside cells such as macrophages, and
unpredictably becomes active in different sites in the lung. “TB drug
development is extremely challenging because a drug has to kill not only
the replicating but the nonreplicating bacteria,” says Feng Wang of the
California Institute for Biomedical Research in La Jolla. To tackle
this problem, Wang, along with Peter Schultz at Scripps Research
Institute, also in La Jolla, and William Jacobs at Albert Einstein
College of Medicine in New York, used a novel screening method to test
the effect of 70,000 compounds on a biofilm of Mtb that simulates the
latent version of the bacterium. One compound popped out of the screen:
TCA1 killed both replicating and nonreplicating <i>Mtb</i> (<a href="http://www.pnas.org/content/110/27/E2510" target="_blank"><i>PNAS</i></a>,
110:E2510-17, 2013). It appeared to attack on two fronts: preventing
bacterial cell-wall synthesis and inhibiting a bacterial enzyme involved
in cofactor biosynthesis, which is likely what makes it effective
against nonreplicating <i>Mtb</i>. (See illustration.) The compound
has since proven successful in both acute and chronic animal models of
TB, and the team is tweaking the chemistry to try and make it even more
potent, says Wang.</div>
<div style="text-align: justify;">
Pharmaceutical company AstraZeneca is similarly developing a drug that
is active against latent bacteria. AZD5847, a type of antibiotic called
an oxazolidinone that is typically used to treat staph infections, is
able to reach and kill <i>Mtb</i> lodging inside macrophages. The
company is currently testing the drug in a Phase 2 efficacy trial in
South Africa involving 75 patients. But developing the compound wasn’t
easy, notes Perros. “We’ve been investing for a decade. It really takes a
long time.”</div>
<h3 style="text-align: justify;">
Seeking a boost</h3>
<div style="text-align: justify;">
<span class="imageBlock" style="display: inline-block; float: right; margin: 0px 0px 10px 10px; width: 310px;"><img alt="" src="http://www.the-scientist.com/images/January2014/TB_21.jpg" height="230" title="" width="310" /><span class="caption">THWARTING
TB: The traditional regimen for TB includes four antibiotics that
primarily inhibit cell-wall synthesis and RNA synthesis. Now,
researchers are looking for new ways to stop the bacterium.<br />
<b>See full infographic:</b> <a href="http://www.the-scientist.com/images/January2014/TB_2_full1.jpg" target="_blank">JPG</a> | <a href="http://www.the-scientist.com/images/January2014/TB_2_full1.pdf" target="_blank">PDF</a></span><span class="reference">CDC/RAY BUTLER; ILLUSTRATION BY THE SCIENTIST STAFF; BASED ON NIAID/WIKIMEDIA COMMONS</span></span>But even if quick-acting, potent drugs were available, <i>Mtb</i>
is so abundant and so well adapted to the human population that the
only true path to eradication is not treatment, but prevention. “There’s
no endgame without a vaccine,” says Aeras’s Evans. “No matter how much
we think we should work on drugs or diagnostics, if we’re not working on
vaccines, we’ll never get to our final goal.”</div>
<div style="text-align: justify;">
The failure of the MVA85A vaccine trial in South Africa last year was
disappointing, but at least a dozen other TB vaccine candidates continue
in clinical trials. Most of these reflect one of two general strategies
for preventing tuberculosis: improve the existing BCG vaccine or, more
commonly, boost its effect with a secondary vaccine. BCG, which is given
to infants, primes the immune response early in life, so booster
vaccines are usually designed to protect adolescents and adults from
later infection. The MVA85A vaccine, for example, was a modified viral
vector expressing Mtb antigen 85A designed as a booster to BCG.</div>
<div style="text-align: justify;">
Vaccine development, however, is hindered by lack of cellular or
molecular markers that directly correlate with immune protection from
TB, making it difficult to predict how well a vaccine might protect
against TB based on the responses of a handful of individuals. “The only
tool we have to make sure a vaccine works is a very large, very
expensive field trial,” says Evans. And that high price tag, as in TB
drug development, has turned numerous pharmaceutical companies off the
pursuit of a TB vaccine.</div>
<div style="text-align: justify;">
But with financial and research support from nonprofit partners like
Aeras—funded by the Bill & Melinda Gates Foundation, among others—a
few companies are still in the game. In collaboration with Aeras, Sanofi
Pasteur is developing a BCG booster vaccine that began Phase 1/2a
safety trials in South Africa last July. It is a recombinant vaccine
made up of two TB proteins fused together and coupled with an adjuvant
called IC31, which really “drives the immune response,” says Sanofi’s
Ryall. Aeras also has another big-pharma partnership with GSK on a
vaccine called M72/AS01e, which has been in Phase 1 and 2 clinical
trials since 2004, including an ongoing trial in Taiwan and Estonia. The
vaccine combines a GSK recombinant antigen called M72, derived from two
tuberculosis-expressed proteins, and a GSK adjuvant called AS01e.</div>
<h3 style="text-align: justify;">
Fresh start</h3>
<div style="text-align: justify;">
<span class="imageBlock" style="display: inline-block; float: right; margin: 0px 0px 10px 10px; width: 310px;"><img alt="" src="http://www.the-scientist.com/images/January2014/TB_3.jpg" height="205" title="" width="310" /><span class="caption">BLASTING
TB: An Aeras employee works on the spray dryer, which creates TB
vaccines in a powder form that can be delivered directly to the lungs.</span><span class="reference">AERAS</span></span>With
TB drugs and vaccines still in early clinical phases, some scientists
are going back to the basics to see if a better molecular understanding
of the bacterium itself could assist these programs. “We need to develop
vaccines, and we need to develop products, but as we do, it’s very
clear that we need to be learning a lot more about the immunobiology [of
TB],” says Evans.</div>
<div style="text-align: justify;">
Last July, for example, Sherman and colleagues published the first
large-scale map of the bacterium’s regulatory and metabolic networks (<a href="http://www.nature.com/nature/journal/v499/n7457/full/nature12337.html" target="_blank"><i>Nature</i></a>,
499:178-83, 2013). The team initially plotted the relationships of 50
Mtb transcription factors, and later, all 200, which control the
expression of the rest of the bacterium’s genes. “Our hope is that by
looking at it in this different way, we can describe different kinds of
drug targets than we have ever done before,” says Sherman.</div>
<div style="text-align: justify;">
The team found that <i>Mtb</i> is remarkably well networked, so that
if a mutation or drug stymies one gene or protein, others step in as
backups, allowing the bacterium to continue functioning normally. But
targeting transcription factors that control whole networks could shut
down an entire system, backups and all. One such network already looks
like a promising drug target—transcription factors controlling a group
of proteins in the bacterium’s cell membrane that pump antibiotics and
other drugs out of the cell. Mtb has so many such pumps that it is
extremely difficult to target multiple pumps for treatment, but genes
that activate numerous pumps at the same time are a far more promising
drug target.</div>
<div style="text-align: justify;">
The idea that scientists will soon develop new, better TB drugs and
vaccines “helps get me up in the morning,” says Sherman. It’s going to
take more breakthroughs than are on the immediate horizon, he adds, “but
if we keep at it, we will get there.” </div>
<div style="text-align: justify;">
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"></td></tr>
<tr><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"><br /></td><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"></td><td class="tr-caption" style="text-align: center;"><br /></td></tr>
</tbody></table>
<span style="color: #a2c4c9;"><span style="font-size: xx-small;">Reff:http://www.the-scientist.com/?articles.view/articleNo/38708/title/Outwitting-the-Perfect-Pathogen/</span></span> </div>
</div>
</div>
<div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com1tag:blogger.com,1999:blog-3006964328834139791.post-66793585473981742682012-05-04T22:46:00.000-07:002013-09-29T06:38:58.468-07:00<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="articleLead">
<h1 id="NewsPostDetailTitle">
<span style="font-size: large;"><span style="font-weight: normal;"><span style="color: red;">INDIA ANNOUNCES TOUGHER RULES FOR OTC ANTIBIOTIC SALES</span></span></span></h1>
<span style="color: magenta;">27 September 2013 </span><br />
<div style="text-align: justify;">
<span style="color: blue;">The Indian government has tightened regulation of sales of over the
counter (OTC) antibiotics following widespread domestic and global
concern over growing antibiotic resistance in the country.</span></div>
<span style="color: blue;">
</span><div style="text-align: justify;">
<span style="color: blue;">In late August this year the Indian Ministry of Health and Family
Welfare, through an official notification, brought 24 antibiotics under a
new ‘Schedule H1’ category of drugs, whose sale without a doctor’s
prescription could attract significant penalties. Pharmacists now have
to document details of the patient, the actual drug and the prescriber
in a separate register, subject to regular inspections by drug control
officials.</span></div>
<br />
<img alt="" height="182" src="http://www.reactgroup.org/uploads/images/News/AB%20h%C3%A4lls%20ut%20p%C3%A5%20recept%20-%20iStock_000015181606Large.jpg" width="450" /><br />
<div style="text-align: justify;">
<span style="color: blue;">The drugs specified in Schedule H1, will be labelled with symbol ‘Rx’
and prominently displayed on the packaging in bold red colour with
following warning: “Schedule H1 Drug-Warning -It is dangerous to take
this preparation except in accordance with the medical advice. Not to be
sold by retail without the prescription of a Registered Medical
Practitioner”. The new rules will come in force in early March 2014.</span></div>
<div style="text-align: justify;">
<span style="color: blue;">
</span></div>
<div style="text-align: justify;">
<span style="color: blue;">In India, the issue of infections caused by multi-drug resistant
bacteria came to the spotlight with the discovery of the highly
resistant New Delhi Metallo beta lactamase-1 or NDM-1, which was found
on European patient who had been to India in 2009. While the Indian
government initially objected to the resistant bacteria being named
after ‘New Delhi’ the controversy also spurred the government to frame a
new antibiotic policy.</span></div>
<div style="text-align: justify;">
<span style="color: blue;">
</span></div>
<div style="text-align: justify;">
<span style="color: blue;">One of the recommendations of the committee set up to frame this
poicy was to regulate the sale of antibiotics by introducing “Schedule
H1” under the Drugs and Cosmetics rules, to regulate sale of
antibiotics.</span></div>
<div style="text-align: justify;">
<span style="color: blue;">
</span></div>
<div style="text-align: justify;">
<span style="color: blue;">The official notification of the list of drugs in Schedule H1 was
however held up over the last couple of years due to protests by the All
India Organization of Chemists and Druggists (AIOCD), which has pointed
out that in many rural areas, licenced doctors are scarce or
unavailable, making many drugs inaccessible to rural populations. Others
fear that new regulations will make life-saving drugs scarce, and lead
to increased costs as they will be routed through the gray market.</span></div>
<div style="text-align: justify;">
<span style="color: blue;">
</span></div>
<div style="text-align: justify;">
<span style="color: blue;">Another problem with regulation of antibiotics sales is that of poor
implementation. Antibiotics are already listed under Schedule H of the
Indian Drug Control Act, which includes over 536 drugs that cannot be
sold without prescription, but this has had little regulatory effect so
far.</span></div>
<div style="text-align: justify;">
<span style="color: blue;">
</span></div>
<div style="text-align: justify;">
<span style="color: blue;">According to the Chennai Declaration, a significant policy statement
made in 2012 by prominent medical professionals and their associations
in India, the problems that India faces in tackling anti-microbial
resistance are multi-factorial. The health infrastructure is very
diverse with uneven standards of hospital infection control or
antibiotic use and across such a diverse country uniform implementation
of restriction of antibiotic sales is a difficult task. In many rural
and remote areas with inaccessible medical facilities, there is hardly
any qualified doctor available to make "prescription only" policy for
sale of antibiotics. Due to the lack of laboratory infrastructure,
collecting and monitoring national data on antimicrobial resistance is a
challenging task.</span></div>
<div style="text-align: justify;">
<span style="color: blue;">
</span></div>
<div style="text-align: justify;">
<span style="color: blue;">Keeping these issues in mind the Chennai Declaration had suggested a
practical approach to regulating antibiotic sales that would be
implementable and not just remain on paper. According to it one of the
strategies that the government should consider is to formulate a list of
key antibiotics with strict monitoring on the dispensing of these
drugs. Once the success of the first stage is ensured step- by- step
introduction of other drugs to the restricted list could be tried.</span></div>
<div style="text-align: justify;">
<span style="color: blue;">
</span></div>
<div style="text-align: justify;">
<span style="color: blue;">The lastest government notification putting a list of selected
antibiotics for greater regulation seems to have taken up this
recommendation of the Declaration and the next move in this context will
be determined by how well this new approach works in practice.</span></div>
<div style="text-align: justify;">
<span style="color: blue;"><span style="color: magenta;">Reff:http://www.reactgroup.org/news/332/18.html</span> </span></div>
<h2 style="text-align: justify;">
<span style="color: blue;"> </span></h2>
<h2>
<img alt="Chairperson and MD, Biocon, Kiran Mazumdar-Shaw, at a press conference in Bangalore on Saturday. Photo: K. Bhagya Prakash" src="http://www.thehindu.com/multimedia/dynamic/01547/TH11_BU_ALZUMAB_1_1547538g.jpg" height="160" title="Chairperson and MD, Biocon, Kiran Mazumdar-Shaw, at a press conference in Bangalore on Saturday. Photo: K. Bhagya Prakash" width="200" /></h2>
<h1 class="detail-title">
<span style="color: red;">Biocon launches drug for treating psoriasis</span></h1>
<h2 style="text-align: justify;">
<span style="font-size: small;"><span style="font-weight: normal;">The drug will be about half the price of similar drugs offered by
multinationals in the country, according to Biocon Chairman and Managing
director Kiran Mazumdar-Shaw.</span></span></h2>
<div style="text-align: justify;">
<span style="font-size: small;"><u>
</u></span></div>
</div>
<div style="text-align: justify;">
<span style="font-size: small;"><u>
</u></span></div>
<div class="body" style="text-align: justify;">
<span style="font-size: small;"><u>
</u></span>Indian biotech major Biocon announced on Saturday that it had launched
its first biologic drug for psoriasis, which affects about 10-20 million
Indians. The drug against the disease, which attacks the immune system,
will be about half the price of similar drugs offered by
multi-nationals in the country, said Chairman and Managing Director
Kiran Mazumdar-Shaw. </div>
<div class="body" style="text-align: justify;">
ALZUMAb, which took the company 10 years to develop, is available in
India at Rs.7,950 a vial. She claimed the drug was the world’s first
“novel” anti-CD6 antibody to treat psoriasis. Ms. Shaw said the cheaper
biologic would enable poorer patients to access a cure for psoriasis.
“Currently, the Indian market for biologics is very small, but the
availability of a cheaper option would expand the size of the market,”
she said. </div>
<div class="body" style="text-align: justify;">
The company was in talks with foreign companies for “partnerships” to
reach out to global markets. “The value of the global market for
biologics to address psoriasis is valued at more than $30 billion,” she
said. “We will start trials in these markets soon,” she said. </div>
<div class="body" style="text-align: justify;">
Ms. Shaw said the success of the company, which she attributed to a
large R&D budget, encouraged it to seek remedies for other
autoimmune diseases such as lupus, rheumatoid arthritis and Sjogren’s
disease. Biocon earned revenues of over Rs.2,500 crore in 2012-13. It
spent 10 per cent of overall revenues on R&D, Ms. Shaw said. </div>
<div class="body">
<span style="color: #6fa8dc;">Reff:http://www.thehindu.com/business/Industry/biocon-launches-drug-for-treating-psoriasis/article5010115.ece</span><br />
<br /></div>
<div style="text-align: justify;">
<span style="color: red;"><u><b><span class="fbPhotosPhotoCaption" data-ft="{"type":45}" id="fbPhotoSnowliftCaption" tabindex="0"><span class="hasCaption"><a href="http://mstar.com.my/berita/cerita.asp?file=%2F2013%2F8%2F1%2Fmstar_berita%2F20130801135035&sec=mstar_berita" target="_blank">LeptoScan2</a> Developed by Dr. Arivudainambi Seenichamy </span></span></b></u></span><span style="color: red;"><u><b><span class="fbPhotosPhotoCaption" data-ft="{"type":45}" id="fbPhotoSnowliftCaption" tabindex="0"><span class="hasCaption"><span class="fbPhotosPhotoCaption" data-ft="{"type":45}" id="fbPhotoSnowliftCaption" tabindex="0"><span class="hasCaption">with </span></span><span class="fbPhotosPhotoCaption" data-ft="{"type":45}" id="fbPhotoSnowliftCaption" tabindex="0"><span class="hasCaption"><span class="fbPhotosPhotoCaption" data-ft="{"type":45}" id="fbPhotoSnowliftCaption" tabindex="0"><span class="hasCaption"><span style="color: red;">Proff. Dato Abdul Rani Bhaman</span>,</span></span></span></span></span></span></b></u></span><span class="fbPhotosPhotoCaption" data-ft="{"type":45}" id="fbPhotoSnowliftCaption" tabindex="0"><span class="hasCaption">Post Doctoral Researcher, University of Putra Malaysia </span></span><span class="fbPhotosPhotoCaption" data-ft="{"type":45}" id="fbPhotoSnowliftCaption" tabindex="0"><span class="hasCaption"><span class="fbPhotosPhotoCaption" data-ft="{"type":45}" id="fbPhotoSnowliftCaption" tabindex="0"><span class="hasCaption"> </span></span>for <span class="-cx-PUBLIC-fbHashtagLink__tagname">leptospirosis</span> it is a disease usually spread by rat urine. <span style="color: blue;"><b>Salute for Tamilan Development. Malaysia Press meet was held on 01/0812013.</b></span></span></span></div>
<img alt="" height="320" src="data:image/jpeg;base64,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" width="320" /><br />
<br />
<br />
<br />
<br />
<header style="background-color: white; line-height: 23.90625px; margin: 0px; padding: 0px;"><hgroup style="margin: 0px; padding: 0px;">
<h3>
<span style="color: red;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><img border="0" src="http://www.vit.ac.in/IndiaTodayRanking2013/Ranking2013B.jpg" height="400" width="290" /> </span></span></h3>
<h3>
<span style="color: red;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><span style="color: black; font-family: Arial;"><a class="hyperlink1" href="http://vit.ac.in/#"><b>VIT moves up to 8<sup>th</sup> position in India Today 2013 ranking</b></a></span></span></span></h3>
<h3>
<span style="color: red; font-family: Georgia, Times New Roman, serif; font-size: large;"><span style="color: blue;"><span style="color: red;">VIT University will reach the top-1.</span> </span></span></h3>
<h3>
<span style="color: blue;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;"> </span></span></h3>
<h3>
<span style="color: blue;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;"> </span></span></h3>
<h3>
<span style="color: blue;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;"> </span></span></h3>
<h3>
<span style="color: blue;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Silver makes antibiotics thousands of times more effective</span></span></h3>
</hgroup><div class="standfirst" style="color: #333333; font-family: arial, helvetica, clean, sans-serif; font-size: 14px; font-weight: bold; margin: 0px; padding: 0px;">
<div style="margin-bottom: 15px; padding: 0px;">
Ancient antimicrobial treatment could help to solve modern bacterial resistance.</div>
</div>
<ul class="authors cleared" style="color: #333333; font-family: arial, helvetica, clean, sans-serif; font-size: 14px; list-style: none; margin: 0px 0px 10px; padding: 0px;">
<li style="float: left; list-style: none; margin: 0px; padding: 0px 0.3em 0px 0px;"><span class="vcard"><a class="fn" href="http://www.nature.com/news/silver-makes-antibiotics-thousands-of-times-more-effective-1.13232#auth-1" style="border: 0px; color: #5c7996; font-weight: bold; text-decoration: none;">Brian Owens</a></span></li>
</ul>
<div class="pubdate-and-corrections" style="color: #333333; font-family: arial, helvetica, clean, sans-serif; font-size: 14px; margin: 0px 0px 15px; padding: 0px;">
<time datetime="2013-06-19" pubdate="">19 June 2013</time></div>
</header><br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<section style="background-color: white; clear: both; color: #333333; font-family: arial, helvetica, clean, sans-serif; font-size: 14px; line-height: 23.90625px; margin: 0px; padding: 0px;"><div class="section" style="clear: both; margin: 0px 0px 15px; padding: 0px;">
<div class="content no-heading cleared main-content" style="border-top-width: 0px; margin: 0px; padding: 1px 0px 0px;">
<div class="img img-right" style="float: right; font-size: 13px; line-height: 1.489em; margin: 0px 0px 10px 10px; max-width: 100%; padding: 0px; width: 302px;">
<div class="img-content" style="background-color: #ececec; margin: 0px; padding: 1px; position: relative;">
<img alt="" src="http://www.nature.com/polopoly_fs/7.11105.1371652685!/image/1.13232_SPL-C0017444-S._maltophilia_bacterium_TEM-SPL.jpg_gen/derivatives/landscape_300/1.13232_SPL-C0017444-S._maltophilia_bacterium_TEM-SPL.jpg" style="border: 0px; display: block; height: auto; max-width: 100%; width: 300px;" /><br />
<div class="caption" style="padding: 5px 5px 4px;">
Silver may help in the fight against drug-resistant bacteria such as <i>Stenotrophomonas maltophilia</i>by easing large antibiotic molecules through the microbes' outer coating.</div>
<div class="credit" style="color: #939393; font-size: 11px; font-style: italic; line-height: 1.461em; padding: 1px 5px 4px; text-transform: uppercase;">
COLOURED TRANSMISSION ELECTRON MICROGRAPH BY CFI/PHE/SCIENCE PHOTO LIBRARY</div>
</div>
</div>
<div class="article-tools" style="clear: right; float: right; margin: 0px 0px 15px 10px; padding: 0px; width: 172px;">
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<aside style="margin: 0px; padding: 0px;"><h2 class="hidden" style="color: #111111; font-size: 14px; left: -9999em; margin: 0px; padding: 0px; position: absolute;">
Article tools</h2>
<ul class="box" style="border: 1px solid rgb(200, 199, 207); font-size: 12px; margin: 0px; overflow: hidden; padding: 10px 5px 5px;">
<li class="print" style="display: block; list-style: disc; margin: 0px; padding: 0px;"><br /></li>
</ul>
</aside></div>
<div style="margin-bottom: 1.65em; padding: 0px;">
Like werewolves and vampires, bacteria have a weakness: silver. The precious metal has been used to fight infection for thousands of years — Hippocrates first described its antimicrobial properties in 400 <span style="font-variant: small-caps;">bc</span> — but how it works has been a mystery. Now, a team led by James Collins, a biomedical engineer at Boston University in Massachusetts, has described how silver can disrupt bacteria, and shown that the ancient treatment could help to deal with the thoroughly modern scourge of antibiotic resistance. The work is published today in <i>Science Translational Medicine</i><sup style="font-size: 12px; line-height: 0; margin-left: 0.15em;"><a class="ref-link" href="http://www.nature.com/news/silver-makes-antibiotics-thousands-of-times-more-effective-1.13232#b1" id="ref-link-1" style="color: #5c7996; text-decoration: none;" title="Morones-Ramirez, J., Winkler, J. A., Spina, C. S. & Collins, J. J. Sci. Transl. Med. http://dx.doi.org/10.1126/scitranslmed.3006276 (2013).">1</a></sup>.</div>
<div style="margin-bottom: 1.65em; padding: 0px;">
“Resistance is growing, while the number of new antibiotics in development is dropping,” says Collins. “We wanted to find a way to make what we have work better.”</div>
<div style="margin-bottom: 1.65em; padding: 0px;">
Collins and his team found that silver — in the form of dissolved ions — attacks bacterial cells in two main ways: it makes the cell membrane more permeable, and it interferes with the cell’s metabolism, leading to the overproduction of reactive, and often toxic, oxygen compounds. Both mechanisms could potentially be harnessed to make today’s antibiotics more effective against resistant bacteria, Collins says.</div>
<h2 style="color: #111111; font-size: 14px; margin: 0px; padding: 0px;">
Resistance is futil</h2>
<div style="margin-bottom: 1.65em; padding: 0px;">
Many antibiotics are thought to kill their targets by producing reactive oxygen compounds, and Collins and his team showed that when boosted with a small amount of silver these drugs could kill between 10 and 1,000 times as many bacteria. The increased membrane permeability also allows more antibiotics to enter the bacterial cells, which may overwhelm the resistance mechanisms that rely on shuttling the drug back out.</div>
<div style="margin-bottom: 1.65em; padding: 0px;">
That disruption to the cell membrane also increased the effectiveness of vancomycin, a large-molecule antibiotic, on Gram-negative bacteria — which have a protective outer coating. Gram-negative bacterial cells can often be impenetrable to antibiotics made of larger molecules.</div>
<div style="margin-bottom: 1.65em; padding: 0px;">
“It’s not so much a silver bullet; more a silver spoon to help the Gram-negative bacteria take their medicine,” says Collins.</div>
<h2 style="color: #111111; font-size: 14px; margin: 0px; padding: 0px;">
Toxic assets</h2>
<div style="margin-bottom: 1.65em; padding: 0px;">
Vance Fowler, an infectious-disease physician at Duke University in Durham, North Carolina, says the work is “really cool” but sounds a note of caution about the potential toxicity of silver. “It has had a chequered past,” he says.</div>
<div style="margin-bottom: 1.65em; padding: 0px;">
In the 1990s, for example, a heart valve made by St. Jude Medical, based in St. Paul, Minnesota, included parts covered with a silver coating called Silzone to fight infection. “It did a fine job of preventing infection,” says Fowler. “The problem was that the silver was also toxic to heart tissue.” As a result the valves often leaked<sup style="font-size: 12px; line-height: 0;"><a class="ref-link" href="http://www.nature.com/news/silver-makes-antibiotics-thousands-of-times-more-effective-1.13232#b2" id="ref-link-2" style="color: #5c7996; text-decoration: none;" title="Grunkemeier, G. L. et al. Eur. J. Cardiothorac. Surg. 30, 20–27 (2006).">2</a></sup>.</div>
<div style="margin-bottom: 1.65em; padding: 0px;">
Before adding silver to antibiotics, “we’ll have to address the toxicity very carefully”, says Fowler. Ingesting too much silver can also cause argyria, a condition in which the skin turns a blue-grey colour — and the effect is permanent.</div>
<div style="margin-bottom: 1.65em; padding: 0px;">
Collins says that he and his colleagues saw good results in mice using non-toxic amounts of silver. But, he adds, there are ways to reduce the risk even further. “We’re also encouraging people to look at what features of silver caused the helpful effects, so they can look for non-toxic versions,” he says.</div>
<div style="margin-bottom: 1.65em; padding: 0px;">
Source: <abbr style="border: 0px;" title="Digital Object Identifier">doi</abbr>:10.1038/nature.2013.13232 <a href="http://www.nature.com/news/silver-makes-antibiotics-thousands-of-times-more-effective-1.13232">http://www.nature.com/news/silver-makes-antibiotics-thousands-of-times-more-effective-1.13232</a></div>
</div>
</div>
</section><span style="color: red; font-family: Verdana, sans-serif;"><b><span style="background-color: white;"><span style="line-height: 19px;">Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis - FDA Accelerated Approval for </span></span><span style="background-color: white; line-height: 21px;">SIRTURO™ (bedaquiline) </span></b></span><br />
<br />
<div style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px;">
<br /></div>
<div style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-align: justify;">
TITUSVILLE, N.J., Dec. 31, 2012 -- Janssen Therapeutics, Division of Janssen Products, LP, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to SIRTURO™ (bedaquiline) Tablets for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The accelerated approval is based on the surrogate endpoint of time to sputum culture conversion.</div>
<div style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-align: justify;">
"SIRTURO™ was first discovered in our laboratories more than a decade ago and it is gratifying to see our discovery and development lead to the accelerated approval of the first TB therapy in 40 years with a new mechanism of action. This underscores our commitment as a company to discover, develop and responsibly deliver innovative medicines that address serious unmet medical needs," said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson.</div>
<div style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-align: justify;">
SIRTURO™ inhibits mycobacterial ATP (adenosine 5'‑triphosphate) synthase, an enzyme that is essential for the generation of energy in Mycobacterium tuberculosis.</div>
<div style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-align: justify;">
<img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg63czoI4O0RPPvX4f2j0CJQydUixPsahcQIZQYANilsaZ7lFJ5XvY4GWWQ-a0uyvqZtb5DSQohzCX8KKv70e1EOZe3PLf4Ubf1wRMZzv9RSyGws1OAyK9wpJIiXzQ0uKfM5Zr_yaq70RE/s320/Screen+shot+2013-01-18+at+14.55.36.png" height="320" width="286" /><img src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjbqiC_TlI5R6ekPtDb-7kNlxFijp1DyFGoYkqD-6-sIRr1eceQXy6BqGVvKw1v1DI-cCR493iQ83UpsPDa93k9dj-BxRzB0OHMfnJyXrKzo4jivHxXF8sSgqDhKRwG79AvN125eTX4yGlS/s320/Tuberculosis_symptoms.png" height="283" style="text-align: left;" width="320" /></div>
<div style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-align: justify;">
Image source from-<a class="irc_hol irc_itl" data-ved="0CAcQjB0wAA" href="http://www.healthcarenets.com/2012/01/tuberculosis-cause-symptoms-and-home.html" style="background-color: #222222; font-family: arial, sans-serif; line-height: 16px; text-align: start; text-decoration: none; white-space: nowrap;"><span class="irc_ho" style="color: #d6d6d6; margin-right: -2px; padding-right: 2px;">www.healthcarenets.com</span></a></div>
<div style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-align: justify;">
SIRTURO™ is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (greater than or equal to 18 years) with pulmonary MDR-TB. Reserve SIRTURO™ for use when an effective treatment regimen cannot otherwise be provided. SIRTURO™ should be administered by directly observed therapy (DOT). This indication is based on analysis of time to sputum culture conversion from two controlled Phase 2 trials in patients with pulmonary MDR-TB. The safety and efficacy of SIRTURO™ for the treatment of latent infection due to Mycobacterium tuberculosis has not been established. The safety and efficacy of SIRTURO™ for the treatment of drug-sensitive TB has not been established. In addition, there are no data on the treatment with SIRTURO™ of extra-pulmonary TB (e.g., central nervous system). Therefore, use of SIRTURO™ in these settings is not recommended.</div>
<div style="text-align: justify;">
<span style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px;"><br /></span></div>
<span style="font-size: x-small;">Source From:</span><br />
<span style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px;">Read more: </span><a href="http://www.fiercebiotech.com/press-releases/fda-grants-accelerated-approval-sirturo-bedaquiline-part-combination-therap#ixzz2UBPSzRDT" style="color: #003399; font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-decoration: none;">FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis - FierceBiotech</a><span style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px;"> </span><a href="http://www.fiercebiotech.com/press-releases/fda-grants-accelerated-approval-sirturo-bedaquiline-part-combination-therap#ixzz2UBPSzRDT" style="color: #003399; font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-decoration: none;">http://www.fiercebiotech.com/press-releases/fda-grants-accelerated-approval-sirturo-bedaquiline-part-combination-therap#ixzz2UBPSzRDT</a><span style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px;"> </span><br />
<span style="font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px;">Subscribe at </span><a href="http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech" style="color: #003399; font-family: Arial, Helvetica, FreeSans, sans-serif; font-size: 13px; line-height: 19px; text-decoration: none;" target="_blank">FierceBiotech</a><span style="font-family: Arial, Helvetica, FreeSans, sans-serif;"><span style="font-size: 15px; line-height: 21px;"><b><br /></b></span></span><br />
<br />
<div id="hedText" style="background-color: white; color: #333333; font-family: Verdana, Tahoma, Helvetica, Arial, sans-serif; font-size: 11px;">
<h1 style="font-family: ProximaNova-SemiBold, Helvetica, Arial, sans-serif; font-size: 36px; font-weight: normal; line-height: 1.2em; margin: 0px;">
Beating Drug-Resistant TB</h1>
<h2 style="font-family: ProximaNova-SemiBold, Helvetica, Arial, sans-serif; font-size: 18px; font-weight: normal; line-height: 1.3em; margin: 0px 0px 10px;">
Reinvestigating a natural antibiotic compound reveals its potential as a tuberculosis drug.</h2>
</div>
<div style="background-color: white; color: #333333; font-family: Verdana, Tahoma, Helvetica, Arial, sans-serif; font-size: 11px;">
<b>By Ruth Williams | September 19, 2012</b></div>
<div class="metaBox" id="social" style="background-color: white; border-bottom-color: rgb(221, 221, 221); border-bottom-style: dashed; border-bottom-width: 1px; border-top-color: rgb(221, 221, 221); border-top-style: dashed; border-top-width: 1px; clear: both; color: #333333; font-family: Verdana, Tahoma, Helvetica, Arial, sans-serif; font-size: 11px; margin: 15px 0px; padding: 5px 2px 6px 0px;">
<img alt="WIKIMEDIA COMMONS" class="attachment-large wp-post-image" src="http://the-scientist.com/wordpress/wp-content/uploads/2012/09/tuberculosis-bacteria2.jpg" height="174" style="border: 1px solid rgb(153, 153, 153); margin: 0px;" width="310" /></div>
<div class="post-content" style="background-color: white; color: #333333; font-family: Verdana, Tahoma, Helvetica, Arial, sans-serif; font-size: 11px; margin: 0px 0px 20px;">
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
An antibiotic produced naturally by common soil bacteria kills <i>Mycobacterium </i>species that cause various human diseases, including tuberculosis (TB), according to a report published Monday (September 17) in <i>EMBO Molecular Medicine</i>. The antibiotic even kills drug-resistant strains that escape current TB treatments.</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
“I seldom get so tickled when I read a paper,” said <a href="http://www.einstein.yu.edu/faculty/6703/william-jacobs-jr/" style="-webkit-transition: all 0.1s ease-in-out; color: #2d86cb; text-decoration: none;">William Jacobs</a>, a microbiologist and immunologist at the Albert Einstein College of Medicine in New York, who did not participate in the research. The emergence of multidrug resistant strains of <i>Mycobacterium tuberculosis</i> “is a big problem,” he said. “This could be a godsend.”</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
Tuberculosis infections are commonly treated with a mixture of antibiotics, including one called isoniazid, which Jacobs described as “the cornerstone of TB therapy.” Unfortunately, the most common drug-resistant strains of <i>M. tuberculosis</i> are isoniazid-resistant, he said.</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
Many researchers, including <a href="http://cole-lab.epfl.ch/" style="-webkit-transition: all 0.1s ease-in-out; color: #2d86cb; text-decoration: none;">Stewart Cole</a>, chair of the microbial pathogenesis department at the École Polytechnique Fédérale de Lausanne in Switzerland, have thus been searching for new <i>M. tuberculosis</i>-killing drugs. “In the past we’ve been working a lot on TB drug discovery using target-based approaches… [but] this has been spectacularly unsuccessful,” said Cole. So instead, he and his colleagues looked back over decades of academic literature searching for reports of natural compounds with <i>M. tuberculosis</i>-killing activity.</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
They found pyridomycin. First described in the 1950s, the drug was reportedly produced by the bacteria <i>Streptomyces pyridomyceticus </i>and <i>Dactylosporangium fulvum</i>. Surprisingly, little was known about pyridomycin—perhaps, Cole suggested, because isoniazid was discovered around the same time and simply stole the limelight.</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
Cole’s team grew cultures of <i>D. fulvum</i> bacteria, figured out how to isolate and purify pyridomycin, and then showed that the drug was indeed capable of killing <i>M. tuberculosis</i>, as well as many other<i>Mycobacterium</i> species, in culture.</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
This indiscriminate <i>Mycobacterium</i>-killing ability is a bonus, said Cole. “One of the problems with isoniazid is that it only works against TB,” he said. “If pyridomycin makes it into the clinic, it could have applications in leprosy or Buruli ulcer or atypical mycobacterial infections that can occur in cystic fibrosis patients.”</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
The team went on to identify the bactericidal target of pyridomycin—a protein called inhA, which is involved in synthesis of bacterial cell wall components. As it happens, inhA is the same protein targeted by isoniazid, but there is a difference in the two drugs’ mechanisms. While isoniazid is a pro-drug that requires activation by an intracellular enzyme called KatG before it can bind to inhA, pyridomycin binds inhA directly.</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
This is an important distinction, explained <a href="http://www.iidmm.uct.ac.za/vmizrahi/index.htm" style="-webkit-transition: all 0.1s ease-in-out; color: #2d86cb; text-decoration: none;">Valerie Mizrahi,</a> director of the Institute of Infectious Disease and Molecular Medicine at Cape Town University, South Africa, who was not involved in the study. The overwhelming majority of drug resistance mutations in <i>M. tuberculosis</i> occur in the KatG<i></i>gene, she explained, and such mutant strains should not be resistant to pyridomycin. Indeed, the team showed that clinical isolates of isoniazid-resistant <i>M. tuberculosis </i>carrying <i>KatG</i> mutations were killed effectively by pyridomycin. “The efficacy against drug resistant forms of <i>M. tuberculosis</i> is particularly encouraging,” Mizrahi said.</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
There is, however, much to be done before pyridomycin can be used in the clinic. “We would [need to] test that it works in animal models and that it is safe and doesn’t have any side effects,” said Cole. “That will take a couple of years.”</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
“It’s a long journey,” agreed Mizrahi, “but the big plus is that they don’t really need to validate inhA as a drug target because inhA is already the most well validated drug target out there… [so] it has got a good head start.”</div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
<b> Source from : </b><a href="http://the-scientist.com/2012/09/19/beating-drug-resistant-tb/" style="font-size: 11px;">http://the-scientist.com/2012/09/19/beating-drug-resistant-tb/</a></div>
<div style="font-size: 12px; line-height: 1.5em; margin-bottom: 1.3em;">
<b>R. C. Hartkoorn et al., “</b><b>Towards a new tuberculosis drug: pyridomycin – nature’s isoniazid,”</b><b><i>EMBO Molecular Medicine</i></b><b>, </b><b>doi:10.1002/emmm.201201689, 2012<br />.</b></div>
</div>
<br />
<b style="background-color: white; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;"><span style="color: red;">What is NDM-1</span></b><br />
<b style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">NDM-1</b><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">, which stands for </span><span style="background-color: white; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;"><b><span style="color: #6aa84f;">New Delhi metallo-beta-lactamase-1</span></b></span><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;"> is a gene (DNA code) carried by </span><img src="http://www.currentreports.info/wp-content/uploads/2012/02/caution-super-bug.jpg" height="166" width="200" /><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">some bacteria. If a bacteria strain carries the NDM-1 gene it is resistant to nearly all </span><a href="http://www.medicalnewstoday.com/articles/10278.php" style="background-color: white; color: #990099; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px; text-decoration: none;" title="What Are Antibiotics? How Do Antibiotics Work?">antibiotics</a><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">, including carbapenem antibiotics - also known as antibiotics of last resort.</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Carbepenems are the most powerful antibiotics, used as a last resort for many bacterial infections, such as </span><i style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">E. coli</i><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;"> and</span><i style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Klebsiella</i><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">. The NDM-1 gene makes the bacterium produce an enzyme which neutralizes the activity of carbepenem antibiotics.</span><br />
<img src="http://www.wired.com/images_blogs/wiredscience/2011/10/klebsiella.jpg" height="140" width="320" /><br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">A bacterium carrying the NDM-1 gene is the most powerful </span><i style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">superbug</i><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;"> around.</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Put simply:</span><br />
<ul style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px; margin-bottom: 20px; margin-left: 15px; margin-top: 20px; padding-left: 15px;"><a href="http://www.futurity.org/wp-content/uploads/2010/08/bacteria_1.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="http://www.futurity.org/wp-content/uploads/2010/08/bacteria_1.jpg" height="218" width="320" /></a>
<li style="padding-bottom: 10px;">NDM-1(New Delhi metallo-ß-lactamase-1) is the gene (the DNA code) found in some types of bacteria</li>
<li style="padding-bottom: 10px;">This gene makes the bacteria produce an enzyme called a carbapenemase - making carbepenem antibiotics ineffective (as well as virtually all other antibiotics).</li>
<li style="padding-bottom: 10px;">Carbepenem antibiotics are extremely powerful and used to fight highly resistant bacteria (when other antibiotics have not worked).</li>
<li style="padding-bottom: 10px;">There are no current antibiotics to combat NDM-1</li>
<li style="padding-bottom: 10px;">There is no research in the pipeline on drugs to combat NDM-1</li>
<li style="padding-bottom: 10px;">A bacterium with the NDM-1 DNA code has the potential to be resistant to all our current antibiotics, as well as new antibiotics which may come into the market in the near future.
<img src="http://img.ezinemark.com/imagemanager2/files/30000234/2010/09/2010-09-09-14-48-16-1-ndm-1-is-found-in-the-e-coli-bacteria-the-cause.jpeg" height="251" width="320" /></li>
<li style="padding-bottom: 10px;">
</li>
</ul>
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">The DNA code can easily jump from one bacteria strain to another through </span><i style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">horizontal gene transfer</i><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">. IF NDM-1 jumps to an already antibiotic-resistant bacterium, there is a risk of seriously dangerous infections which would spread rapidly from human-to-human. These infections might be untreatable.</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">UK doctors say they had only ever seen a few cases which are resistant to carbapenems - and these had not been able to transfer resistance to other bacteria. The fact that NDM-1 can easily transfer to different bacteria strains is very worrying, they say.</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Currently (12 August 2010) we know that some strains of bacteria, such as </span><i style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">E. coli</i><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;"> and</span><i style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Klebsiella pneumoniae</i><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;"> carry the NDM-1 gene.</span><br />
<br />
<h2 class="blue_sea_paddingtop" style="background-color: white; color: #0f3f9f; font-family: Arial, Helvetica; font-size: 17px; margin-top: 25px;">
The origin of NDM-1</h2>
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">The gene was discovered by Young and team and was named after New Delhi, the Indian capital. The gene is widespread in India and Pakistan, especially in hospitals.</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Europeans who have undergone hospitalization in the Indian subcontinent have brought NDM-1 back to Europe. A significant number of Europeans who brought the gene back to Europe had undergone cosmetic surgery in India/Pakistan because it is cheaper there.</span><br />
<h2 class="blue_sea_paddingtop" style="background-color: white; color: #0f3f9f; font-family: Arial, Helvetica; font-size: 17px; margin-top: 25px;">
How untreatable is this superbug?</h2>
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">So far, doctors in the UK have managed to fight these infections with a combination of several different medications. However, scientists have detected some bacterial strains that are resistant to ALL antibiotics.</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">The only way to currently combat the spread of NDM-1 is through surveillance, prompt identification and isolation of infected patients, disinfecting hospital equipment, and thorough hand-hygiene procedures in hospitals. This is going to be a challenge and will require international cooperation.</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">NDM-1 is widespread in India and Pakistan, and it has reached Europe, the USA, Canada and Australia.</span><br />
<br />
<h2 class="blue_sea_paddingtop" style="background-color: white; color: #0f3f9f; font-family: Arial, Helvetica; font-size: 17px; margin-top: 25px;">
Alerts in the UK</h2>
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">The Health Protection Agency (HPA), UK has issued an </span><a href="http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1248854045473" rel="nofollow" style="background-color: white; color: #990099; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px; text-decoration: none;" target="_blank">alert</a><span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;"> to medical professionals. Below is part of the alert:</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Allowing patterns of human travel and migration, and the many UK residents who receive medical treatment in India, we believe that UK healthcare will be repeatedly challenged by imported producers. These organisms mostly are resistant to ALL antibiotics except polymyxins and, less consistently, tigecycline. The activity of obscure agents (fosfomycin, arbekacin and isepamicin) and novel compounds is under investigation, but none is readily available for therapy. In these circumstances it is vital to detect producers and to prevent their onward transmission.</span><br />
<br />
<span style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Actions advised</span><br />
<ul style="background-color: white; color: #333333; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px; margin-bottom: 20px; margin-left: 15px; margin-top: 20px; padding-left: 15px;">
<li style="padding-bottom: 10px;">Be alert to the increase in carbapenemase-producing Enterobacteriaceae, and the growing importance of NDM -1 enzyme.</li>
<li style="padding-bottom: 10px;">Recognise exposure to healthcare systems in India and Pakistan as additional major risk factors for infection or colonization with multiresistant, carbapenemase-producing Enterobacteriaceae</li>
<li style="padding-bottom: 10px;">Refer ALL carbapenem-resistant Enterobacteriaceae to ARMRL, except (i) <i>Proteus </i>spp. and <i>Morganella</i> spp. With borderline resistance only to imipenem (common in these genera) and (ii) <br />E. cloacae with intermediate resistance to ertapenem only, as these are generally just derepressed for AmpC. NDM production will be investigated promptly.</li>
<li style="padding-bottom: 10px;">Patients infected with producers should be isolated to prevent onward transmission in hospitals; carriage in the patient's faecal flora should be examined for producers of the same or different species; similar screening of close unit contacts should be strongly considered.</li>
</ul>
<span style="background-color: white; color: #b45f06; font-family: Arial, Helvetica; font-size: 14px; line-height: 20px;">Sources: The Lancet Infectious Diseases, Health Protection Agency (HPA), and the BBC.</span></div>
<div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com1tag:blogger.com,1999:blog-3006964328834139791.post-53390689901778507582011-06-15T04:34:00.001-07:002012-03-02T22:23:37.953-08:00<div dir="ltr" style="text-align: left;" trbidi="on"><span class="Apple-style-span" style="background-color: white; color: #333333; font-family: Helvetica,Arial,serif; font-size: 12px; line-height: 19px;"></span><br />
<div><br />
<span class="Apple-style-span" style="background-color: white; color: blue; font-family: Helvetica,Arial,serif; font-size: large; line-height: 19px;"><b>SUPER BUG</b></span></div><br />
<div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;"><b>31 May 2011</b> - The doctors are cheerful when they walk into Pradeep Aggarwal's room. They crack jokes with the middle-aged man, who has been admitted into a posh south Delhi hospital, and tell him he is improving. But once outside his room, their faces tell a different story. They know his end is near. They feel helpless, knowing there are no medicines strong enough to help him survive.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Aggarwal has a chest infection caused by <i>pseudomonas aeruginosa</i>, a bacterium that has become resistant to all antibiotics.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">"We feel so helpless watching such patients slide to a certain death even though modern medicine, good hospitals, good doctors and sophisticated healthcare technology are all available," says a microbiologist at the hospital. Everyday, doctors are being confronted with the growing reality that various strains of bacteria are getting tougher to kill. The World Health Organisation says that the level of resistance to drugs used to treat common infectious diseases is reaching a crisis point.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Why is this happening? Overuse and improper use of antibiotics over decades has now spawned bacteria that are immune to the drugs we have. Bacteria are microorganisms that thrive everywhere, even the cleanest of homes. They are constantly attacking our bodies, and pose the risk of causing ear infections, throat infection, tuberculosis, etc. By and large, our immune systems can fight off the bacteria. But every once in a while, the bacteria in our body reproduce faster than our immune system can kill them, and we suffer from illnesses. And we call upon a variety of drugs to restore normalcy.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Antibiotics (the term 'anti-bacterial' is often used interchangeably with 'antibiotic') were seen as miracle drugs, powerful enough to kill the harmful bacteria. But over the years, careless overuse and under use of antibiotics have helped bacteria develop immunity to powerful drugs, making them difficult or impossible to tackle. Alexander Fleming would never have imagined this, when he discovered penicillin in 1928.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;"><b>Careless use of anti-biotics</b></span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Doctors all over India widely over-prescribe antibiotics, hoping for a quick definite cure apart from keeping pharmaceutical companies happy. These firms generously offer gifts and holiday trips abroad, some of them disguised as visits to attend medical conferences, to doctors who push their products. Over prescription of antibiotics ends up promoting new strains of harmful bacteria that develop immunity. "Often, doctors prescribe carelessly often succumbing to aggressive marketing and incentives offered by the drug company," says Dr. Ramachandran, of the University College of Medical Sciences in New Delhi.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">At the lower levels of the pharma industry too, drugs are peddled incessantly. Just stand outside any chemist's shop, and it is quite easy to see how he plays the doctor, doling out antibiotics to patients. The drugstore clerk knows his customers are hoping to cut down on the exorbitant consultant fees of a doctor, and exploits this, assuring them that his chosen medicine is what the doctor would prescribe anyway. But, without the training and skills of a physician, these clerks make mistakes. The pills themselves are sometimes wrong, and often the dosages are excessive. And the consequences can be devastating to patients.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;"></span></div><table align="right" bgcolor="000000" border="0" cellpadding="0" cellspacing="0" style="width: 240px;"><tbody>
<tr><td><table border="0" cellpadding="8" cellspacing="2"><tbody>
<tr bgcolor="#ffffd9" class="sh" style="font: normal normal normal 11px/normal verdana; text-decoration: none;"><td><img src="http://www.indiatogether.org/health/images/2011/hlt-superbug.jpg" vspace="4" width="230" /><br />
Doctors all over India widely over-prescribe antibiotics, hoping for a quick definite cure apart from keeping pharmaceutical companies happy. These firms generously offer gifts and holiday trips abroad, some of them disguised as visits to attend medical conferences, to doctors who push their products.<br />
<img src="http://www.indiatogether.org/images/related.jpg" vspace="4" /><br />
<span class="blt" style="color: black; font: 11px arial;"> • </span> <a href="http://www.indiatogether.org/2008/feb/hlt-tobacco.htm" style="color: #111111; text-decoration: none;">Sitting on an epidemic</a><br />
<span class="blt" style="color: black; font: 11px arial;"> • </span> <a href="http://www.indiatogether.org/2006/nov/hlt-phfi.htm" style="color: #111111; text-decoration: none;">Will PHFI be meaningful?</a><br />
<span class="blt" style="color: black; font: 11px arial;"> • </span> <a href="http://www.indiatogether.org/2006/nov/hlt-tbdanger.htm" style="color: #111111; text-decoration: none;">TB, the gravest danger</a></td></tr>
</tbody></table></td></tr>
</tbody></table><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;"><img align="right" height="470" src="http://www.indiatogether.org/images/pixels/ffffff.jpg" width="7" />But even when there is no fraud, things can go wrong. Many of us, especially in urban India, reach out to antibiotics at the smallest excuse, hoping for a quick cure from a slight illness. In fact, many patients<i>want</i> their doctors to prescribe antibiotics to them. But any good physician will tell you that the best way to treat something like a cold is to ignore it for a week. The doctor would also jocularly admit that antibiotics would also take seven days anyway!</span><br />
<div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Many patients also do not complete the dosage once they feel better, hoping to save money. This helps the bacteria bounce back again after a lull, and when they return they have learnt how to deal with the antibiotic and still survive. The next time around, the antibiotic isn't good enough to tackle the tiny beast. Explains Dr. Sushma Yevale, a well known Pune gynecologist: "As many patients do not use antibiotics exactly the way they are prescribed, the bacteria progresses and rapidly grows to become resistant."</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">For each of us, over-prescription and incomplete use are passing acts, whose conequences are invisible. But taken as a whole, they add up to a monster we cannot control with the drugs at hand. All of us, each in our own little ways, have been cultivating Superbugs systematically for a very long time.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;"><b>Alarming proportions</b></span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">A survey by the World Health Organization on antibiotic use in Delhi reveals that 53 per cent of Delhiites self-prescribe antibiotics; one in four stop taking them once they feel better, instead of finishing the course; 25 per cent treat regular fever with antibiotics; and almost 18 per cent of the physicians prescribe antibiotics for non-specific fever, cough and even diarrhea. Elsewhere in India, the results are likely to be similar.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Dr. Ashutosh Shukla, Head of Internal Medicine at Artemis Health Institute, Gurgaon, says, "The emergence of Superbugs is a serious issue that needs to be immediately addressed. But it would need a lot of coordinated action from the medical fraternity and the Health Ministry to create systems to stop the over-the-counter sale of prescription drugs, and put in place a strong education campaign telling patients that overuse of antibiotics can be counter-productive and dangerous."</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Dr. Shukla recently returned from a training programme at the Harvard Medical School. He found that in the out-patient department, the staff administer only the basic antibiotics and not the high end ones that doctors prescribe in India. He often finds that a lot of his patients have upper respiratory tract infections that does not require antibiotics. But most of them, he found, had already self-administered a dose of antibiotics before visiting the hospital.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;"><b>Can India deal with the challenge in time?</b></span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Last year, the leading medical journal <i>Lancet</i> ran a report claiming the presence of superbugs in New Delhi's water, calling it NDM-1. The Director General of the Indian Council of Medical Research, Dr. V M Katoch was quick to reject the report, saying that there was nothing to worry, as such organisms were found everywhere. In April this year, the Prime Minister's Office has asked for a detailed report on the issue from the Health Ministry.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Whatever this report may discover, it was troubling to note that the first respnse of the government, faced with a serious issue, is to deny it. That does not bode well for efforts to contain the potential damage.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Dr Atul Kothari, clinical microbiologist at Max Hospital in New Delhi, says that in the coming years, India may see Superbugs exploding all over. Kothari who has worked for many years both in the United Kingdom and India, says that Superbugs in the west had a low prevalence in the eighties, but in the nineties, they exponentially increased. The situation in India now is like the one that was in the west in the eighties. Doctors agree that the danger for India is real, and there is no room for complacency.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">It is not just India's problem alone. Experts like the scientists at the Centers for Disease Control and Prevention in the United States say that over prescription and misuse of antibiotic drugs are the main causes of bacterial resistance. It says that up to half of the roughly 100 million prescriptions for antibiotics written each year in the United States are unnecessary!</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">But the developed countries are ahead on one count. The west, in particular, has woken up to this healthcare problem. It has got actively involved in tackling it. For instance, hospitals in the west are now forced by the government to publish their hospital-acquired infection rates on the web and make it available to government sources. If the hospital has a bad infection control rate, it would get less money in terms of government grants. So, there is a constant pressure to clean up, to regulate and monitor.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Besides, general practioners in developed western countries are under pressure to reduce their prescriptions of antibiotics, and this is constantly monitored. Then, there are educational programmes in schools where students are trained to tell their parents about the dangers of overusing antibiotics. This is especially helpful, as it is parents who lunge for the drugs even if the child has nothing more than a common cold. This programme has greatly helped create awareness. But nothing of this kind is happening in India.</span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">But the situation in India is very different. There is no National Regulatory Authority in India to fix the problem of Superbugs. There is no central body that publishes these figures. The result is that the danger spreads and no one seems to know. Warns Dr. Kothari: "If India does not recognise increasing bacterial resistance as a problem, it will never deal with it in time." </span></div><div align="justify"><span class="contents2" style="font: 12px/1.5 arial,helvetica; text-decoration: none;">Reff: <a href="http://www.indiatogether.org/2011/may/hlt-superbug.htm">http://www.indiatogether.org/2011/may/hlt-superbug.htm</a></span></div></div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com1tag:blogger.com,1999:blog-3006964328834139791.post-62690797503839830482011-04-14T23:23:00.000-07:002011-04-15T00:26:53.713-07:00India declares its National Policy for containment of Antimicrobial Resistance<div dir="ltr" style="text-align: left;" trbidi="on">Ref: <a href="http://www.nicd.nic.in/ab_policy.pdf">http://www.nicd.nic.in/ab_policy.pdf</a><br />
<br />
</div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com0tag:blogger.com,1999:blog-3006964328834139791.post-85009573519264869162011-04-07T06:13:00.000-07:002011-04-07T06:19:07.336-07:00NDM-1 superbugs found in seepage, tap water<div dir="ltr" style="text-align: left;" trbidi="on"><img src="http://onlinesamachars.com/wp-content/uploads/2011/04/TH07-BUGS-BRSC_523440f-300x200.jpg" /><br />
<span class="Apple-style-span" style="color: #333333; font-family: Verdana; line-height: 18px;"></span><br />
<h1 class="topstory-title" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; color: black; font-family: Arial, san-serif; font-size: 28px; font-weight: bold; line-height: 32px; margin-bottom: 10px; margin-left: 0px; margin-right: 0px; margin-top: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px;">NDM-1 superbugs found in seepage, tap water</h1><span id="date" style="color: #666666; font-family: Arial, san-serif; font-size: 10px;">Published on April 7, 2011 by <a href="http://onlinesamachars.com/author/admin/" style="color: #666666; text-decoration: none;" title="Posts by admin">admin</a> · No Comments</span><br />
<div style="font-size: 12px;">NDM-1 gene found in 51 seepage and two tap water samples in New Delhi</div><div style="font-size: 12px;">Gram-negative bacterial strains with NDM-1 (New Delhi Metallo-beta-lactamase-1) gene, also called the superbug, have now been detected in drinking water and seepage water samples collected from several sites in New Delhi. Seepage samples were collected from water pools found in streets or rivulets.</div><div style="font-size: 12px;">The findings have been published online today (April 7) in <em>The Lancet Infectious Diseases </em>journal.</div><div style="font-size: 12px;">The NDM-1 gene enables Gram-negative bacterial strains to become resistant to carbapenem, a powerful antibiotic. Bacteria that carry the antibiotic resistant gene were found in two drinking-water samples and 51 seepage water samples.</div><div style="font-size: 12px;">The two drinking-water samples were collected from west of the Yamuna River in the district of Ramesh Nagar and from south of the Red Fort, respectively. The seepage samples that tested positive for the NDM-1 gene were collected close to Sir Ganga Ram Hospital, Gol Market and other sites.</div><div style="font-size: 12px;"><strong>No panic situation</strong></div><div style="font-size: 12px;">Since none of the tap water samples had stable plasmids, “the situation has not yet [become] utterly miserable,” writes Mohd Shahid in an accompanying Comment piece in the journal. Dr. Shahid is from the Department of Medical Microbiology, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, U.P.</div><div style="font-size: 12px;">In all, the researchers had collected 50 drinking-water samples (public tap water samples) and 171 seepage samples from sites within a 12 km radius of central New Delhi.</div><div style="font-size: 12px;">70 sewage effluent samples from Cardiff Wastewater Treatment Works were also collected as control samples.</div><div style="font-size: 12px;">“Some samples contained multiple NDM-1 positive species,” the authors write. “20 NDM-1 positive strains were present in the samples, including <em>E. coli</em> and <em>K. pneumonia</em> [that causes pneumonia], …and pathogenic species <em>Shigella boydii</em> and <em>V. cholera</em> [that cause dysentery and cholera, respectively].”</div><div style="font-size: 12px;">NDM-1 was in the news in August last year when the same journal reported that 37 U.K. patients who had undergone elective and cosmetic surgeries in India and two neighbouring countries (Pakistan and Bangladesh) were harbouring the drug-resistant bacterial strains.</div><div style="font-size: 12px;"><strong>Human gut bacteria</strong></div><div style="font-size: 12px;">But the latest finding clearly indicates that the drug-resistant bacterial strain carrying NDM-1 gene is no longer a hospital-born infection, but is found in the environment.</div><div style="font-size: 12px;">The authors of the study have found that NDM-1 gene has also spread to families of bacteria that populate the human gut and cause urinary tract infection, diahorrea, to name a few. It has also spread to pathogenic bacteria species that cause cholera and dysentery.</div><div style="font-size: 12px;">It is indeed really possible for the NDM-1 gene that confers antibiotic resistance to move from one species to another.</div><div style="font-size: 12px;">The easy spread is made possible as the NDM-1 gene is carried in the plasmids of the Gram-negative bacteria. And the plasmids can move from one bacterium to another of its kind, and even to different bacterial species.</div><div style="font-size: 12px;"><strong>Role of temperature</strong></div><div style="font-size: 12px;">But a bigger concern is the temperature conditions under which the plasmids carrying the antibiotic resistant gene get transferred to another bacterium.</div><div style="font-size: 12px;">It was highest at 30 degree C. In fact, it was 1 to 10,000 times higher than at 25 degree C, and 1 to 10,00,000 times higher than at 37 degree C.</div><div style="font-size: 12px;">What does that mean in terms of public health? 30 degree C is the average peak temperature in New Delhi, and is also the temperature that lies within the daily range of temperature of the city for seven months of the year — from April to October.</div><div style="font-size: 12px;">The April to October period includes the monsoon season. And that would mean that the spread of the antibiotic resistant strains to other areas is easily facilitated by rain water carrying the seepage water.</div><h3 style="font-size: 16px; font-weight: bold; line-height: 20px; margin-bottom: 5px; margin-left: 0px; margin-right: 0px; margin-top: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px;">Route of transmission</h3><div style="font-size: 12px;">That not all patients from the U.K. or other European countries who had visited India had any hospitalisation history underlines the fact that bacteria with this resistance are present in the environment.</div><div style="font-size: 12px;">The authors state: “NDM-1 is widely disseminated in New Delhi and has spread into key enteric pathogens.”</div><div style="font-size: 12px;">Faecal-oral transmission would have been the possible route for the <em>E. coli</em> with the NDM-1 gene to enter the gut of these patients.</div><div style="font-size: 12px;">In fact, about 650 million people in India do not have access to toilets. And only about 60 per cent of New Delhi’s population is served by the sewerage system.</div><div style="font-size: 12px;">“The data presented by [the authors] clearly show the grave potential for widespread dissemination of NDM-1 in the environment,” writes Shahid.</div><div style="font-size: 12px;">“NDM-1 gene has just got into the environment but is yet to be established in tap water as the isolates from the tap water did not have stable plasmids. So there is no need to worry right now if we implement policies to control the spread,” said Dr. Shahid to this Correspondent. “The sample size is also small and only two tap water samples tested positive for NDM-1 gene.”</div><div style="font-size: 12px;">But it is a fact that “broad epidemiological and environmental studies are now needed in other cities in India, especially those that are adjacent to New Delhi,” Dr. Shahid writes in the comment</div><span class="Apple-style-span" style="font-size: xx-small;">Reff:</span><a href="http://onlinesamachars.com/"><span class="Apple-style-span" style="font-size: xx-small;">http://onlinesamachars.com/</span></a></div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com1tag:blogger.com,1999:blog-3006964328834139791.post-36596521377694711242011-04-02T13:13:00.000-07:002011-04-02T23:08:43.144-07:00Congrats to INDIAN team - World cup 2011<div dir="ltr" style="text-align: left;" trbidi="on"><img alt="Indian Team for World Cup 2011 - India Announce Cricket Team For ..." src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjIyxl8JxFKRmwbqCmouiiNSTRarKCGKdkBAfEA8OuRv_FwDjKrvSzAxqgElAiECrqcDcZBGF44vIoyMTLN7fi6WYJngCq-k5CSDjFth54xQwkFydVEGgP7UM5Xay6EphRIbzsu43AkKcNY/s400/Champions.jpg" /><br />
<span class="Apple-style-span" style="color: #3f3f3f; font-family: georgia; font-size: 15px; line-height: 20px;">An inspired India on Saturday night regained the coveted World Cup after 28 years as they suppressed Sri Lanka with a six-wicket victory in a nerve-wrecking final to script a glorious new chapter in their cricketing history. </span><span class="Apple-style-span" style="color: #3f3f3f; font-family: georgia; line-height: 20px;"><span class="Apple-style-span" style="font-size: x-small;">The Times of India</span></span><br />
Thanks to Indian Team</div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com0tag:blogger.com,1999:blog-3006964328834139791.post-66822944147958832312010-12-13T02:09:00.000-08:002010-12-17T05:37:24.432-08:00All India Radio Talk<div class="MsoNormal" style="line-height: 16.8pt; margin-bottom: 0in; mso-outline-level: 3;"><span style="color: #00264c; font-size: 12pt;"><a href="http://save-antibiotics.blogspot.com/2010/01/radio-talk-by-nramesh-iimars-trichy.html"><b><span style="color: #38761d; font-family: Verdana, sans-serif; font-size: 13.5pt; text-decoration: none;">A Radio Talk by N.Ramesh - IIMAR`s Trichy coordinator on Superbug and IIMAR</span></b></a><span class="Apple-style-span" style="font-family: Times, serif;"></span></span></div><div class="MsoNormal" style="line-height: 19.2pt;"><span style="color: #000099; font-family: Arial, sans-serif; font-size: 10pt;">On 19th November 2010, All India Radio Tiruchirappalli broadcasted at 9.00 PM, a talk in Tamil by N.Ramesh- IIMAR`s Trichy coordinator- on the topic " Superbug and IIMAR"<br />
N.Ramesh is a Doctoral Research Scholar at the Department of Microbiology, School of Life Sciences,Bharathidasan University, Tiruchirappalli.Tamil Nadu,India. </span><br />
<span style="color: red; font-family: Arial; font-size: x-small;"><strong>follow the link to heare this audio</strong></span><br />
<a href="http://h1.ripway.com/pnramesh/Superbug%20part%20-1.mp3">http://h1.ripway.com/pnramesh/Superbug%20part%20-1.mp3</a><br />
<a href="http://h1.ripway.com/pnramesh/Superbug%20part%20-2.mp3">http://h1.ripway.com/pnramesh/Superbug%20part%20-2.mp3</a><span style="color: #dd5010; font-family: Arial, sans-serif; font-size: 10pt;"><a href="http://h1.ripway.com/pnramesh/Superbug%20part-2.mp3"></a></span><br />
<br />
<br />
</div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com1tag:blogger.com,1999:blog-3006964328834139791.post-84582734650864516252010-08-13T06:58:00.000-07:002010-08-13T06:58:09.120-07:00Super Bug _NDM1 @ INDIA<h2 class="art-PostHeader" style="font-family: Georgia, 'Times News Roman', Times, serif; font-size: 18px; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; line-height: inherit; margin-bottom: 0.2em; margin-left: 0px; margin-right: 0px; margin-top: 0.2em; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; text-decoration: none; text-indent: 0px; text-transform: none; word-spacing: normal;"><a class="PostHeader" href="http://ic-technews.com/health/340-deadly-superbug-ndm-1-bacteria-gene-resistant-to-most-powerful-antibiotics" style="font-family: Georgia, 'Times News Roman', Times, serif; font-size: 18px; font-style: normal; font-weight: bold; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; text-align: left; text-decoration: none;"><span class="Apple-style-span" style="color: blue;">Deadly Superbug NDM-1 bacteria gene resistant to most powerful antibiotics</span></a></h2><div><br />
</div><div style="text-align: justify;"><span class="Apple-style-span" style="color: #4a4a4a; font-family: Georgia, 'Times News Roman', Times, serif; font-size: 12px;">The Lancet Infectious Diseases Journal published a report on Wednesday, Aug 11 on the new gene called New Delhi metallo-beta-lactamase (NDM-1). This super bug is resistant to almost all kinds of antibiotics including the most powerful class called carbapenems. Super bug is said to be invaded in UK. The reports say that the bacteria NDM-1 has travelled back with NHS patients who went South Asian countries like India and Pakistan for medical treatments. Though 50 cases of such bacterial infection have been identified in UK yet the scientists apprehend that it could spread globally.</span><span class="Apple-style-span" style="color: #4a4a4a; font-family: Georgia, 'Times News Roman', Times, serif; font-size: 12px;"> </span></div><div style="text-align: justify;"><span class="Apple-style-span" style="color: #4a4a4a; font-family: Georgia, 'Times News Roman', Times, serif; font-size: 12px;"><br />
</span></div><div style="text-align: justify;"><span class="Apple-style-span" style="color: #4a4a4a; font-family: Georgia, 'Times News Roman', Times, serif; font-size: 12px;">So far as India is concerned NDM-1 could prove threat to the health of Indians. The reason is that people in India indulge in self medication; they buy certain antibiotics over the counter without doctor’s prescription sometimes. Moreover they are not customized to continue their treatment as advised by doctor and get down with same clinical problem again and again. The doctors believe that common antibiotics have become ineffective on Indian people. </span></div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com4tag:blogger.com,1999:blog-3006964328834139791.post-18043972443400468142010-06-16T07:31:00.000-07:002010-06-16T07:31:15.962-07:00IIMAR is working towards an `Agreement for cooperation` with ` ReAct - Action on Antibiotic Resistance` - of Sweden.<div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: Calibri; font-size: small;">IIMAR –ReAct cooperation – Availability of funds</span></div><div class="MsoNormal" style="margin: 0in 0in 10pt;"><span style="font-family: Calibri; font-size: small;">Dear Friends</span></div><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt 0.5in; text-align: justify;"><span style="font-family: Calibri; font-size: small;">IIMAR<span> </span>is working towards an `<b>Agreement for cooperation`<span> </span>with ` ReAct - Action on Antibiotic Resistance` - of Sweden</b>. The agreement generally stipulates that we will work together towards a program for management of Antibiotic Resistance in particular in India and also cooperate internationally. </span></div><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt 0.5in; text-align: justify;"><span style="font-family: Calibri; font-size: small;">The program will generally include</span></div><div style="line-height: normal; margin: 0in 0in 0pt 0.5in; text-align: justify;"><span style="font-family: Symbol;"><span><span style="font-size: small;">·</span><span style="font-family: 'Times New Roman'; font-size-adjust: none; font-size: 7pt; font-stretch: normal; font-style: normal; font-variant: normal; font-weight: normal; line-height: normal;"> </span></span></span><span style="font-family: Calibri; font-size: small;">Antibiotic resistance awareness and management - Field activities</span></div><ul style="margin-top: 0in;" type="disc"><li class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; text-align: justify;"><span style="font-family: Calibri; font-size: small;">Antibiotic resistance awareness and management -Web based activities </span></li>
<li class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; text-align: justify;"><span style="font-family: Calibri; font-size: small;">South Asian, South East Asian and Asian Initiatives </span></li>
<li class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt; text-align: justify;"><span style="font-family: Calibri; font-size: small;">Aid to post-graduate students in Indian Universities for projects on infections, resistant bacteria, resistance management and similar projects</span></li>
</ul><div class="MsoNormal" style="line-height: normal; margin: 0in 0in 0pt 0.5in; text-align: justify;"><br />
</div><div class="MsoNormal" style="margin: 0in 0in 10pt; text-indent: 0.25in;"><b><span style="font-family: Calibri; font-size: small;">ReAct is likely to fund this programme to the tune of about Rs 10 Lakhs.</span></b></div><div class="MsoNormal" style="margin: 0in 0in 10pt; text-indent: 0.25in;"><span style="font-size: small;"><span style="font-family: Calibri;">It is agreed that the fund will be hosted by <span lang="EN-GB">the R.D. Gardi Medical College at Ujjain. <b>The fund needs to be utilised before December 2010.</b></span></span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt; text-indent: 0.25in;"><span lang="EN-GB"><span style="font-size: small;"><span style="font-family: Calibri;">Now that we have funds we can energise our activities.</span></span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt; text-indent: 0.25in;"><b><span lang="EN-GB"><span style="font-size: small;"><span style="font-family: Calibri;">I request all of you to please come forward to take part in this programme to conduct these activities at your home base. While you volunteer for your time, IIMAR provides funds. The activities can happen anywhere in India. Please give wide publicity to this information</span></span></span></b></div><div class="MsoNormal" style="margin: 0in 0in 10pt; text-indent: 0.25in;"><span lang="EN-GB"><span style="font-size: small;"><span style="font-family: Calibri;">Regards </span></span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt; text-indent: 0.25in;"><span lang="EN-GB"><span style="font-size: small;"><span style="font-family: Calibri;">Dr. A.J Tamhankar</span></span></span></div><div class="MsoNormal" style="margin: 0in 0in 10pt; text-indent: 0.25in;"><span lang="EN-GB"><span style="font-size: small;"><span style="font-family: Calibri;">N.Ramesh </span></span></span></div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com0tag:blogger.com,1999:blog-3006964328834139791.post-5455670760025539822010-05-17T06:42:00.001-07:002010-05-19T22:34:26.820-07:00United Kingdom Photos<a href="http://picasaweb.google.com/home">http://picasaweb.google.com/home</a><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com1tag:blogger.com,1999:blog-3006964328834139791.post-73231010167158784012010-02-24T06:31:00.001-08:002010-02-24T06:31:41.829-08:00All India Radio Talk<span class="Apple-style-span" style="color: #333333; font-family: Georgia, Times, serif; font-size: 11px;"></span><br />
<h2 class="date-header" style="color: #4c4700; font: normal normal bold 86%/normal 'Trebuchet MS', Trebuchet, Arial, Verdana, sans-serif; letter-spacing: 0.2em; line-height: 1.4em; margin-bottom: 0.5em; margin-left: 0px; margin-right: 0px; margin-top: 1.5em; text-transform: uppercase;">THURSDAY, JANUARY 7, 2010</h2><div class="post hentry" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: dotted; border-bottom-width: 1px; margin-bottom: 1.5em; margin-left: 0px; margin-right: 0px; margin-top: 0.5em; padding-bottom: 1.5em;"><a href="" name="5340690704549149650"></a><h3 class="post-title entry-title" style="color: #00264c; font-size: 16px; font-weight: normal; line-height: 1.4em; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0.25em; padding-bottom: 4px; padding-left: 0px; padding-right: 0px; padding-top: 0px;"><a href="http://save-antibiotics.blogspot.com/2010/01/radio-talk-by-nramesh-iimars-trichy.html" style="display: block; text-decoration: none;"><span class="Apple-style-span" style="color: #38761d;"><b><span class="Apple-style-span" style="font-size: medium;">A Radio Talk by N.Ramesh - IIMAR`s Trichy coordinator on Antibiotic Resistance and IIMAR</span></b></span></a></h3><div class="post-header-line-1"></div><div class="post-body entry-content" style="line-height: 1.6em; margin-bottom: 0.75em; margin-left: 0px; margin-right: 0px; margin-top: 0px;"><span style="color: #000099;">On 7th January 2009, All India Radio Tiruchirappalli broadcasted at 7.00 AM, a talk in Tamil by N.Ramesh- IIMAR`s Trichy coordinator- on the topic " Antibiotic Resistance and IIMAR"<br />
N.Ramesh is a Doctoral Research Scholar at the Department of Microbiology, School of Life Sciences,Bharathidasan University, Tiruchirappalli.</span><div style="clear: both;"></div></div><div class="post-footer" style="color: #4c4700; font: normal normal normal 78%/normal 'Trebuchet MS', Trebuchet, Arial, Verdana, sans-serif; letter-spacing: 0.1em; line-height: 1.4em; margin-bottom: 0.75em; margin-left: 0px; margin-right: 0px; margin-top: 0.75em; text-transform: uppercase;"><div class="post-footer-line post-footer-line-1"><span class="post-author vcard">POSTED BY <span class="fn">DR. A. J. TAMHANKAR, NATIONAL COORDINATOR FOR INDIAN INITIATIVE FOR MANAGEMENT OF ANTIBIOTIC RESISTANCE (IIMAR)</span> </span><span class="post-timestamp">AT <a class="timestamp-link" href="http://save-antibiotics.blogspot.com/2010/01/radio-talk-by-nramesh-iimars-trichy.html" rel="bookmark" style="color: #00264c; text-decoration: none;" title="permanent link"><abbr class="published" style="border-bottom-style: none; border-color: initial; border-left-style: none; border-right-style: none; border-top-style: none; border-width: initial;" title="2010-01-07T10:44:00+05:30">10:44 AM</abbr></a> </span><span class="post-comment-link"><a class="comment-link" href="https://www.blogger.com/comment.g?blogID=3570059377635293362&postID=5340690704549149650&isPopup=true" onclick="javascript:window.open(this.href, "bloggerPopup", "toolbar=0,location=0,statusbar=1,menubar=0,scrollbars=yes,width=400,height=450"); return false;" style="color: #00264c; margin-left: 0.6em; text-decoration: none;">1 COMMENTS</a></span><span class="post-icons"></span></div><div><br />
</div><div class="post-footer-line post-footer-line-2"><span class="post-labels"></span></div><div class="post-footer-line post-footer-line-3"><span class="post-location"></span></div></div></div><div class="inline-ad"></div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com0tag:blogger.com,1999:blog-3006964328834139791.post-48334413051406167002010-02-24T06:13:00.000-08:002010-02-24T06:13:05.530-08:00Antibiotic Resistance Awareness Campaign<span class="Apple-style-span" style="color: #333333; font-family: Georgia, Times, serif; font-size: 11px; line-height: 17px;"></span><br />
<div align="justify"><strong><span style="color: #000066;">A Highly successful Antibiotic Resistance Awareness Campaign at Tiruchirapalli, Tamil Nadu, India - A report by Dr. A. J. Tamhankar</span></strong></div><div align="justify">An <strong>Antibiotic Resistance Awareness</strong> <strong></strong><strong>Campaign</strong> of the <span style="color: black;"><strong>INDIAN INITIATIVE FOR MANAGEMENT OF</strong></span><strong><span style="color: black;"> ANTIBIOTIC RESISTANCE (IIMAR)</span><span style="color: #000066;"> </span></strong>was conducted at Tiruchirapalli- (also called `Trichy`) - in Tamil Nadu, in India on 25th August 2009. The programme consisted of explanation of the emerging problem of Antibiotic Resistance at a person to person level <img alt="" border="0" id="BLOGGER_PHOTO_ID_5379349732916477314" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjazaVZR84xnhFytcXxWwTFdNWv8XYmtEIHyx47h-0BOqHeB0o1qZ6WegV2-pBIug06A2pVL3MdhcUok-kEH29DyjmuEGE-scifrreNdhQmR5_xMFlRr7k53iZtSv7-hp-v9-o47jQ5H1w/s320/ramesh+1.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: right; height: 132px; margin-bottom: 10px; margin-left: 10px; margin-right: 0px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 152px;" />to eminent persons of Tiruchirapalli and also to the <em>Physicians, Pharmacists and the general public </em>in<em> </em>Trichy. This was accompanied by the <em>distribution of Antibiotic Resiatance awareness</em> <em>brochures</em> to all these people. The brochures addressed to the Physicians, Pharmacists and the public at large were different from each other. The programme started with the release of the brochures at the hands of <strong>Dr.M.Ponnavaikko,</strong> the <strong>Hon’ble Vice </strong><strong>Chancellor of the Bharatidasan University (BDU)</strong>. The inaugural function was attended by the Registrar of BDU, and also the faculty of the university. In the photograph we see (from right) Dr.N.Thajuddin -HOD, Dept of Microbiology, Dr.M.Ponnavaikko -the Vice Chancellor (releasing the first brochure to the Registrar), Mr. Nachimuthu Ramesh -Trichy Coordinator of IIMAR campaign, Dr.T.Ramasamy -Registrar of BDU<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhEPgcXU2i7HiQl5o4P86RQNkQGfnh__EcFpmTuYMA9rvLKZjrvnkXzvgf6VW_U9mck1Y8hUOeCML1Mo6Bit7arPSj4pX4EagJRjTu87kR9JYx4Ev39Fn4UwAFYnthvOQSRQbZU79ZX8fk/s1600-h/ramesh2.JPG" style="color: #00264c; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5379370855174543682" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhEPgcXU2i7HiQl5o4P86RQNkQGfnh__EcFpmTuYMA9rvLKZjrvnkXzvgf6VW_U9mck1Y8hUOeCML1Mo6Bit7arPSj4pX4EagJRjTu87kR9JYx4Ev39Fn4UwAFYnthvOQSRQbZU79ZX8fk/s320/ramesh2.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: right; height: 128px; margin-bottom: 10px; margin-left: 10px; margin-right: 0px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 159px;" /></a>and Dr.V.RajeshKannan and Dr. Dhanasekaran of the Dept of Microbiology. All these dignitaries joined IIMAR. The campaign at Trichy was organised in collaboration with two other organizations- the district unit of the <strong>Human </strong><strong>Rights Organization</strong> and a local Social Organization <strong>"Sneham".</strong>Amongst the next two photos, in the first we see smt. <strong>S. Sujatha</strong>, Worshipful <strong>Mayor of Tiruchirappalli</strong>, and in the second, the <strong>commissioner of the Municipal corporation of Trichy</strong>,<strong>Mr. T.T. Balsamy</strong>, (extreme left in the next photo) being given the brochures and being<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjdS2vbAF2J5T7LBGnmbJlv8c2dnxGUw3U-tG8AhYQkT3KjyNlhBrkxfYorfx1o9OifUOj6u8SJnWUfx6C4YLq0ELVjyfcApsNKn8YNQ9DvZb8SWjafk4thvJpQW-0Fg5o72-SqYG19pG0/s1600-h/ramesh3.JPG" style="color: #00264c; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5379379639999879458" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjdS2vbAF2J5T7LBGnmbJlv8c2dnxGUw3U-tG8AhYQkT3KjyNlhBrkxfYorfx1o9OifUOj6u8SJnWUfx6C4YLq0ELVjyfcApsNKn8YNQ9DvZb8SWjafk4thvJpQW-0Fg5o72-SqYG19pG0/s320/ramesh3.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: right; height: 109px; margin-bottom: 10px; margin-left: 10px; margin-right: 0px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 142px;" /></a></div><div align="justify">explained the problem of antibiotic resistance. Also present in the photo</div><div align="justify">are Trichy District Coordinator of Human Rights Organization and also of `Sneham` Social Organization, Mr.Paul Guna Loganath and Mr. N. Ramesh. After campaigning with the Mayor and the commissioner of the city, the campaign moved to the District collector`s office. The <strong>District Collector, Mr.T. Soundiah</strong> (in the centre of the next <a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhWRpFIPLuVhD5uSvvlH5nCMqSfGkBA9rGBfpfo2x_MOmZjRMO7geWJIS96eIrDZYOZwDLwOK3YgBP1Z6aD0GCJ_szXcHhchVhyphenhyphenG2EXNZKOW9G-qxFATTPI1hQebxv9RMirnssO8BdS_IE/s1600-h/ramesh6.JPG" style="color: #00264c; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5379794129217254002" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhWRpFIPLuVhD5uSvvlH5nCMqSfGkBA9rGBfpfo2x_MOmZjRMO7geWJIS96eIrDZYOZwDLwOK3YgBP1Z6aD0GCJ_szXcHhchVhyphenhyphenG2EXNZKOW9G-qxFATTPI1hQebxv9RMirnssO8BdS_IE/s320/ramesh6.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: right; height: 114px; margin-bottom: 10px; margin-left: 10px; margin-right: 0px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 135px;" /></a>photograph) was explained the importance of the rational use of antibiotics and also how if we fail to use the antibiotics rationally, how our future generations will suffer. Mr. Soundiah assured his full cooperation to the campaign and joined IIMAR. At the collectorate with Mr. Soundaiah was also present the <strong>Dean of the Government Hospital Dr. C. Balasubramanian </strong>(seen in the photo along with Mr. soundiah), who offered his full cooperation to the campaign and Joined IIMAR. The full support of Dr. C. Balasubramanian was amply evident by his actions <a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiXt9Hgxas0HYO7bSaIlrgGH0-3a4TrOLeyzX5nEjv75eo-sRKVxMR9JegbsIgOeF8NhNmfEwG_0J1BWSnKewDE5G2bABaUt8XnnJYOz9cQFGxkihrhWJdgLrrr31TNwf710Ux-tcH3dQs/s1600-h/ramesh9.JPG" style="color: #00264c; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5379429421974515442" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiXt9Hgxas0HYO7bSaIlrgGH0-3a4TrOLeyzX5nEjv75eo-sRKVxMR9JegbsIgOeF8NhNmfEwG_0J1BWSnKewDE5G2bABaUt8XnnJYOz9cQFGxkihrhWJdgLrrr31TNwf710Ux-tcH3dQs/s320/ramesh9.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: left; height: 127px; margin-bottom: 10px; margin-left: 0px; margin-right: 10px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 145px;" /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj8R8Vg7CagcYwru2-no06BovgvRx9X9RpUsniuf8SrFMP2fv9kvYf70tLR9tORw0AFB-eDWW6EIlicc1a4Fcj9JSVNIE-t4VHNRlwhewthFuzcKNQB7opv5t6fflOxHR73z5fE_7zoiY8/s1600-h/ramesh8a.JPG" style="color: #00264c; text-decoration: none;"></a>and here, in the photo on the left we can see the Public Relations Officer of the hospital exhibiting the brochures on the notice board. The IIMAR campaigners then distributed the brochures amongst <strong>the physicians</strong> of the hospital as well as the physicians of the <strong>Geethanjali medical</strong> <strong>centre</strong> and discussed the problem of antibiotic resistance with them.<br />
The <strong>Pharmacists</strong> form an important <img alt="" border="0" id="BLOGGER_PHOTO_ID_5379434151308543234" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhmDcvCQP4xt0SC-UrUXcyttO8ddIlbI6fU18SkuZDIjI5UoscXjnrgyjGEmJbymbuPn-uHZE3u8l-goWTsKWne2FH_cHBR4DIrNfQICAKFkwAuRdEEJC7A0WN_TFkB862O4-MXgDnb-E8/s320/ramesh16.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: right; height: 112px; margin-bottom: 10px; margin-left: 10px; margin-right: 0px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 151px;" />link in the supply of antibiotics to the customers/patients and they need to be involved in any campaign on rational use of antibiotics. Several Pharmacists were contacted. The photo shows the campaigners explaining to the staff of VASAN Medicals -with the help of brochures specially made for pharmacists-, how the pharmacists can help in the rational use of antibiotics.<br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiesmWyHbrhXl1UDIUMg7PAnyR2Vfxe7_SN2vGhD1DGyUYt6wkdO1tuUKDwo86BX7BjtFW4x2O1blgZcvJ3cZjPzQnUD5l59fzmABTssaM9ojriC2b0sFTyGCfjZOKEy3LBX2er9EaVfD4/s1600-h/ramesh7.JPG" style="color: #00264c; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5379436147571040882" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiesmWyHbrhXl1UDIUMg7PAnyR2Vfxe7_SN2vGhD1DGyUYt6wkdO1tuUKDwo86BX7BjtFW4x2O1blgZcvJ3cZjPzQnUD5l59fzmABTssaM9ojriC2b0sFTyGCfjZOKEy3LBX2er9EaVfD4/s320/ramesh7.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: left; height: 137px; margin-bottom: 10px; margin-left: 0px; margin-right: 10px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 154px;" /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhhbNtnxg-Lxvfh2AB_dAapVdWhJ8JGkUX3Ocj_er-hJM4BTM5Z_RIccL7VBRKYhJCQYhreCpt23mHhw8Yj01w6waztJNMoOmgVA7YP5m58oT6H-J-cDk5iiACn5Q0qo_K7HlJ7cujy_Pk/s1600-h/ramesh8.JPG" style="color: #00264c; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5379436309262527682" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhhbNtnxg-Lxvfh2AB_dAapVdWhJ8JGkUX3Ocj_er-hJM4BTM5Z_RIccL7VBRKYhJCQYhreCpt23mHhw8Yj01w6waztJNMoOmgVA7YP5m58oT6H-J-cDk5iiACn5Q0qo_K7HlJ7cujy_Pk/s320/ramesh8.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: right; height: 130px; margin-bottom: 10px; margin-left: 10px; margin-right: 0px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 163px;" /></a>The <strong>legal fraternity</strong> is an influencial component of any community. The <strong>practicing lawyers</strong> (photo on the left) and also the sub-judge <strong>Mr. M. Gomathi Nayagam, Secretary, District Legal service Authority,Tiruchirappalli </strong>(seen in the photo on the right) were also contacted in the campaign and made aware of the spreading antibiotic resistance problem.</div><div align="justify"><br />
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgegmC4cw70F7G6XR_NSAeG0swNw6_WEMxWEDienTlKWxuU9BbJLQWXmYF6dmtXfEwIsuFuOXkMm-RKtQ8CMJyMP89Z5k_SuC-6Yq510-bxttbTapePPdG5ejfmj8I0cVDQO6MOT4k8qf0/s1600-h/ramesh10.JPG" style="color: #00264c; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5379438614445574162" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgegmC4cw70F7G6XR_NSAeG0swNw6_WEMxWEDienTlKWxuU9BbJLQWXmYF6dmtXfEwIsuFuOXkMm-RKtQ8CMJyMP89Z5k_SuC-6Yq510-bxttbTapePPdG5ejfmj8I0cVDQO6MOT4k8qf0/s320/ramesh10.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: left; height: 110px; margin-bottom: 10px; margin-left: 0px; margin-right: 10px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 143px;" /></a><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgt69ds-FkS0PgFAZIHopHiGt4-aqDp1nvjocYijpT_9uXEPUEE5cnDL5-2c2zLNejAv6x28y490mqRzbubgIgG_PbbYIA4SN0nxgct_f1PZ7i79p1IrYCeKDioXNBXBW3qbZkdReF2KZU/s1600-h/ramesh14.JPG" style="color: #00264c; text-decoration: none;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5379439121346197474" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgt69ds-FkS0PgFAZIHopHiGt4-aqDp1nvjocYijpT_9uXEPUEE5cnDL5-2c2zLNejAv6x28y490mqRzbubgIgG_PbbYIA4SN0nxgct_f1PZ7i79p1IrYCeKDioXNBXBW3qbZkdReF2KZU/s320/ramesh14.JPG" style="border-bottom-color: rgb(0, 38, 76); border-bottom-style: solid; border-bottom-width: 1px; border-left-color: rgb(0, 38, 76); border-left-style: solid; border-left-width: 1px; border-right-color: rgb(0, 38, 76); border-right-style: solid; border-right-width: 1px; border-top-color: rgb(0, 38, 76); border-top-style: solid; border-top-width: 1px; float: right; height: 116px; margin-bottom: 10px; margin-left: 10px; margin-right: 0px; margin-top: 0px; padding-bottom: 4px; padding-left: 4px; padding-right: 4px; padding-top: 4px; width: 144px;" /></a>The campaign also had in its programme the distribution of the brochures to the <strong>public at large</strong> and also explaining to them the importance of rational use of antibiotics. In this effort, IIMAR was joined by The<strong> District Zonal Planning Officer, </strong>who personally came along with the campaigners to distribute the brochures. The<strong> brochures for the common man were made in the</strong> <strong>local language `Tamil`.</strong> The local populace showed a keen interest in understanding the problem.</div><div align="justify">The campaign coincided with the <strong>Global Antibiotic Resistance Partnership- GARP -India Inaugural meeting</strong> in New delhi In India<strong>.</strong></div><div align="justify">(Note: Separate brochures for the Physicians, Pharmacists and the Public at large have been prepared by Dr. A. J. Tamhankar using material from several authentic sources.)</div><div align="justify"><br />
<strong>Mr N. Ramesh-Ph.D scholar at BDU, Trichy and IIMAR`s star campaigner at Trichy</strong> joins me to report further----</div><div align="justify">"Under the overall guidance of the National Coordinator of IIMAR- Dr.A. J.Tamhankar we planned to conduct the Antibiotic Resistance awareness programme in and around Trichy region. For that we prepared attractive multi-colour brochures with the direction of the National Coordinator-IIMAR and planned to distribute them to Common people, Physicians and Pharmacist using separate brochure for each of them. The local advisory committee consisted of Dr.V.RajeshKannan and Dr.N.Thajuddin. The Vice-chancellor was kind enough to give permission to the campaign and very aptly suggested to make the brochures for the common man in the local `Tamil` language. We distributed a total of 2500 brochures during the campaign day. All the higher authorities responded very nicely and suggested to conduct the campaign in municipal wards as well as in villages because this is the first time any`Antibiotic resistance awareness campaign` was being conducted in the area. They have promised to support such an effort. The doctors at the Geethanjaly medical centre asked us to conduct this programme in rural areas. The pharmacist also responded very well and they were asking that the `government must develop rules regarding the judicial use of antibiotics and do something with the prescription format also`. They suggested to-do the awareness programme on radio and Television.<br />
And finally, we distributed the brochures to common people on Uraiyur four road, GH road, Thillai Nager, Collector off road, in and around Trichy bus stand and in and around university campus. Everybody`s response was very good; especially our university staff -they voluntarily took extra copies from us to distribute in their local area. Now, daily at least one or two of them tell me that `the brochures have given very good information which we did not know till now and now we realise what are all the problems that will come if we do not use antibiotics properly. "</div><div align="justify"><strong>Acknowledgement:</strong>IIMAR expresses its sincere thanks to the members of the local advisory committee- Dr.V.Rajesh Kannan and Dr.N.Thajuddin of the Dept of Microbiology, Bharathidasan University who supported whole heartedly this awareness programme and saw to it that it became a great success. IIMAR also expresses thanks to the Vice Chancellor and Registrar of the BharatiDasan University for giving permission to conduct this programme under its auspices and also staff, scholars, and students of the university who cooperated in this effort. Last but not the least we wholeheartedly thank the local press for their cooperation and particularly the `Malaimalar` daily news paper for publishing reports of the event. And Off course thanks to all our well wishers and many annonymous supporters.</div><div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com6tag:blogger.com,1999:blog-3006964328834139791.post-72344819105302285752010-02-24T05:45:00.000-08:002013-07-05T02:19:56.304-07:00Important Web Links for Researchers<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="text-align: left;">
</div>
<ol>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><a href="http://www.thesciencejobs.com/"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.thesciencejobs.com/</span></span></span></a></span></span><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Job Seeking</span></span></span></span></span></li>
<li><a href="http://www.education.nic.in/announceschol.asp"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.education.nic.in/announceschol.asp</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Abroad Scholarship Announcement</span></span></span></span></span></li>
<li><a href="http://helpbiotech.blogspot.com/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://helpbiotech.blogspot.com/</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> -</span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> Fellowship Vacancy in India</span></span></span></span></span></li>
<li><a href="http://www.findaphd.com/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.findaphd.com/</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> -</span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Find a PhD in and Around the World</span></span></span></span></span></li>
<li><a href="http://www.conferencealerts.com/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.conferencealerts.com/</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Find Conferences in and Around the World all disciplines</span></span></span></span></span></li>
<li><a href="http://save-antibiotics.blogspot.com/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://save-antibiotics.blogspot.com/</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Antibiotic Resistance Management - India</span></span></span></span></span></li>
<li><a href="http://save-antibiotics.blogspot.com/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.manitham.net/</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Human Rights Organization</span></span></span></span></span></li>
<li><a href="http://www.successcds.net/Entrance-Exam/CSIR-UGC-NET-National-Eligibility-Test-JRF.html"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.successcds.net/Entrance-Exam</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Common Eligibility Test</span></span></span></span></span></li>
<li><a href="http://www.protocol-online.org/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.protocol-online.org</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">To find a Protocol</span></span></span></span></span></li>
<li><a href="http://mtcc.imtech.res.in/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://mtcc.imtech.res.in/</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">To get the Microbial Culture </span></span></span></span></span></li>
<li><a href="http://www.atcc.org/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.atcc.org/</span></span></span></span></span></a><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">To Get the Microbial Culture</span></span></span></span></span></span></li>
<li><span class="Apple-style-span" style="color: #990000; font-family: Times,'Times New Roman',serif;"><a href="http://www.genome.wisc.edu/resources/internet.htm"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.genome.wisc.edu/resources/internet.htm</span></span></span></span></a><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - Strains collections and E.coli genome project</span></span></span></span></li>
<li><span class="Apple-style-span" style="color: #990000; font-family: Times,'Times New Roman',serif;"><a href="http://cgsc.biology.yale.edu/index.php"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://cgsc.biology.yale.edu/index.php</span></span></span></span></a><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - E.coli strains collection</span></span></span></span></li>
<li><span class="Apple-style-span" style="color: #990000; font-family: Times,'Times New Roman',serif;"><a href="http://www.microrao.com/identify.htm"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.microrao.com/identify.htm</span></span></span></span></a><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - Micro important Journals and informations</span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><a href="http://www.imc9.info/links.htm"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.imc9.info/links.htm</span></span></span></span></a><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> </span></span></span></span><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">- </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Mycology societies around the world</span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><a href="http://www.fj4d.com/fmj/IP_MICRO.HTM"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.fj4d.com/fmj/IP_MICRO.HTM</span></span></span></span></a><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> -</span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> Medical journal lists</span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><a href="http://www.careerafter12th.com/?p=399"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.careerafter12th.com/?p=399</span></span></span></span></a><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> </span></span></span></span><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">- </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">Carrier after 12th </span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><a href="http://www.biotechnologist2020.com/2008/06/icgeb-italy-vacancy-for-research.html"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.biotechnologist2020.com/2008/06/icgeb-italy-vacancy-for-research.html</span></span></span></span></a><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> </span></span></span></span><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">- Vacancy</span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><a href="http://www.tgw1916.net/bacteria_abis.html"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.tgw1916.net/bacteria_abis.html</span></span></span></span></a><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> </span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><a href="http://www.sgm.ac.uk/membership/"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.sgm.ac.uk/membership/</span></span></span></a><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span><span class="Apple-style-span"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">General Microbiology Society - Fellowships and PhD positions in Microbiology</span></span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><a href="http://www.sgm.ac.uk/links/"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.sgm.ac.uk/links/</span></span></span></span></a><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"> - </span></span></span><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">General Microbiology Society - Science Links</span></span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"><a href="http://www.well.ox.ac.uk/home">http://www.well.ox.ac.uk/home</a> - Welcome Trust Oxford University</span></span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"><a href="http://www.medicinenet.com/script/main/hp.asp">http://www.medicinenet.com/script/main/hp.asp</a> - Medical </span></span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"><a href="http://www.pdr.net/Default.aspx">http://www.pdr.net/Default.aspx</a>-Drug information</span></span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"><a href="http://www.ischemo.org/">http://www.ischemo.org/</a> - International society of Chemotherapy</span></span></span></span></span></span></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"><a href="http://www.idsociety.org/">http://www.idsociety.org/</a> - Infectious Disease Society of America</span></span></span></span></span></span></li>
<li><a href="http://antibioticinformation.blogspot.com/2005/11/what-are-antibiotics.html"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://antibioticinformation.blogspot.com/2005/11/what-are-antibiotics.html</span></span></span></span></span></span></a></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.theantibioticsblog.com </span></span></span></span></span></span></li>
<li><a href="http://www.englishpage.com/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://www.englishpage.com</span></span></span></span></span></span></a></li>
<li><a href="http://aangilam.blogspot.in/"><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;">http://aangilam.blogspot.in</span></span></span></span></span></span></a></li>
<li><span class="Apple-style-span" style="font-family: Times,'Times New Roman',serif;"><span class="Apple-style-span" style="color: blue;"><span class="Apple-style-span" style="color: #990000;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: x-large;"><span class="Apple-style-span" style="background-color: #b6d7a8;"><a href="http://www.englishleap.com/grammar/tenses">http://www.englishleap.com/grammar/tenses</a></span></span></span></span></span></span></li>
</ol>
</div>
<div class="blogger-post-footer">Enable post feed additions</div>Dr.Ramesh Nachimuthuhttp://www.blogger.com/profile/00506339942156012442noreply@blogger.com1